An integrated framework for functional dissection of variable expressivity in genetic disorders

Jiawan Sun[1]*, Serena Noss[1]*, Deepro Banerjee[1], Venkata Hemanjani Bhavana[1], Corrine Smolen[1], Maitreya Das[1], Belinda Giardine[1], Anisha Prabhu[1], David J Amor[2,3], Kate Pope[2], Paul J Lockhart[2,3], and Santhosh Girirajan[1,4].

1. Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA 16802
2. Department of Paediatrics, University of Melbourne, Melbourne, Australia
3. Bruce Lefroy Centre, Murdoch Children's Research Institute, Melbourne, Australia
4. Huck Institutes of the Life Sciences, University Park, PA 16802

Correspondence:
Santhosh Girirajan
205A Huck Life Sciences Building
Pennsylvania State University
University Park, PA 16802
E-mail: sxg47@psu.edu

ABSTRACT

Disease-associated variants can lead to variable phenotypic outcomes, but the biological

mechanisms underlying this variability remain poorly understood. We developed a framework to

investigate this phenomenon using the 16p12.1 deletion as a paradigm of variable expressivity.

Using induced pluripotent stem cell models from affected families and CRISPR-edited lines with

the 16p12.1 deletion, we found that the deletion and secondary variants in the genetic

background jointly influenced chromatin accessibility and expression of neurodevelopmental

genes. Cellular analyses identified family-specific phenotypes, including altered inhibitory

neuron production and neural progenitor cell proliferation, which correlated with head-size

variation. CRISPR activation of individual 16p12.1 genes variably rescued these defects by

modulating key signaling pathways such as TGF-β and PI3K-AKT. Integrative analyses further

identified regulatory hubs, including transcription factors FOXG1 and JUN, as mediators of

these effects. Our study provides a functional framework for investigating how individual genetic

architectures contribute to phenotypic variability in genetic disorders.

INTRODUCTION

In contrast to Mendelian disorders with straightforward genotype to phenotype relationships, variants associated with complex disorders often lead to variable clinical features[1,2]. This phenomenon of variable expressivity is particularly true for rare copy number variants (CNVs), such as deletions and duplications within chromosomal regions 1q21.1, 15q13.3, and 22q11.2, which have been associated with variable neurodevelopmental outcomes and have also been identified in population controls[3]. For example, the 22q11.2 deletion, classically known to cause DiGeorge syndrome, is associated with intellectual disability and developmental delay (ID/DD), autism, and congenital heart defects, and it accounts for about 1% of individuals with schizophrenia[4,5]. The approximately 500-kbp 16p12.1 deletion, encompassing eight genes, represents an ideal model to study variable expressivity of disease-associated variants for several reasons. *First*, the deletion is associated with a wide range of phenotypic outcomes, including ID/DD, autism, congenital anomalies, and epilepsy in affected children, as well as psychiatric features such as schizophrenia, depression, and anxiety in adolescents and adults, with varying levels of severity[6–12]. *Second*, unlike syndromic CNVs such as 17p11.2 deletion in Smith-Magenis syndrome or 5q35 deletion in Sotos syndrome[3], that mostly occur *de novo*, the 16p12.1 deletion is inherited in over 90% of affected individuals from parents with milder cognitive or neuropsychiatric features[13]. The high inheritance rate allows us to assess phenotypic outcomes in multiple carriers from the same family. *Third*, specific patterns of rare variants in the genetic background ("secondary variants") correlated with distinct phenotypic trajectories associated with the deletion[14]. In fact, modifier roles of secondary variants have also been reported as contributing to phenotypic variability in both monogenic and complex neurodevelopmental disorders, including in individuals affected by 7q11.23 duplication and 16p11.2 duplication [2,3,15,16]. However, the molecular basis by which these CNVs confer disease susceptibility and interact with secondary variants to produce variable outcomes remains poorly understood.

Previous studies have shown the utility of induced pluripotent stem cells (iPSC) to recapitulate complex biological processes *in vitro*, enabling investigations into the molecular etiology of neurodevelopmental disorders[17–19]. However, these studies have typically focused on aggregate analysis of subjects with the same primary variant, such as the 16p11.2 and 22q11.2 deletion, or the same phenotype, such as autism and schizophrenia, without investigating the variability among these subjects[20–22]. Thus, the effects of disease-associated variants within the

context of an individual's genetic background remain unexplored. Here, we developed a

framework to dissect the mechanistic basis of variable expressivity in iPSC models of the

16p12.1 deletion **(Figure 1)**. By integrating multi-omics profiling, CRISPR/dCas9-mediated

gene activation, and family-based analyses, we demonstrate that phenotypic trajectories

associated with 16p12.1 deletion are shaped by the combinatorial effects of the deletion and

secondary variants through the modulation of key signaling pathways. We further identified

regulatory hubs that mediate these effects, including transcription factors (TFs) FOXG1 and

JUN, along with genes in the regulatory network. We propose a conceptual shift from a focus on

single causal variants to a system-level understanding of individual genetic architecture,

advancing more effective precision medicine strategies.

89	**RESULTS**
90	**Generation and characterization of iPSC models for 16p12.1 deletion**
91	To model the effects of the deletion on neuronal development in an isogenic setting, we created a
92	465-kbp 16p12.1 deletion in the HD_01 line, derived from a healthy donor, using a
93	CRISPR/Cas-9-based strategy **(Supplementary Figure 1A-E)**. To study the effects of the
94	16p12.1 deletion under different family-specific genetic backgrounds, we reprogrammed iPSC
95	lines from peripheral blood mononuclear cells derived from 12 individuals from three families
96	**(Figure 1A-B).** As controls, we used iPSC lines (HD_01 and HD_02; obtained from NINDS
97	repository) from unrelated healthy male and female donors, as well as a HD_01 line transfected
98	with empty vector as a CRISPR control. These 16 iPSC lines were then differentiated to neural
99	progenitor cells (NPC) and immature (iMN) and mature neurons (MN) using dual-SMAD
100	inhibition[18] (see **Methods, Figure 1B**). RNA sequencing was performed at all four cell stages,
101	while ATAC-seq was performed for iPSC and NPC lines (**Figure 1A**). We confirmed reduced
102	expression of 16p12.1 deletion genes including *UQCRC2, POLR3E, MOSMO*, and *CDR2*, as
103	well as reduced ATAC-seq signals across the region **(Supplementary Figure 2A-B,**
104	**Supplementary Table 1-2).** The expression of expected gene markers were robust for each
105	differentiation cell state, such as expression of *SOX2*, *POU5F1*, and *FUT4* for iPSC; *SOX2*,
106	*HES1*, *NES*, and *EMX2* for NPC; and *MAP2*, *DLG4*, *NCAM1*, and *RBFOX3* for neurons
107	**(Supplementary Figure 2C)**, and ATAC-seq peak revealed differences in chromatin
108	accessibility near cell-type-specific genetic markers such as *POU5F1*, *SOX2,* and *HES1*,
109	confirming the expected cell identities across the lines **(Supplementary Figure 2D).**

Figure 1. Overview of the integrated framework using 16p12.1 deletion iPSC models. (**a**) Experimental design. WGS was performed on DNA isolated from blood or iPSCs derived from healthy donors and individuals in the three families. RNA-seq was performed across all four differentiation stages and ATAC-seq was performed at iPSC and NPC stages. (**b**) Representative images of neural-converted cells stained with different markers for distinct cell stages (scale bars, 20 μm). **(c)** Overview of experimental strategy used to investigate how the 16p12.1 deletion and secondary variants contribute to phenotypic variability. The core questions driving the experiments within the framework are also shown.

Combined effects on gene expression related to neurodevelopment

We compared all deletion lines to nondeletion lines at each cell stage and found that the most significantly differentially expressed genes (DEGs) were those within the deleted region (**Supplementary Figure 2A, Supplementary Table 1)**. This suggested that a combined analysis may obscure the downstream effects of the deletion due to variability between samples, likely due to differences in their genetic background. To isolate the direct impact of the deletion, we compared the CRISPR-edited 16p12.1 deletion line to its isogenic control. This approach is commonly used in iPSC models of disease[23] to control for the effects of the genetic background. DEGs identified in NPC, iMN, and MN were enriched for neurodevelopmental and psychiatric disorder genes from the DisGeNET and published datasets[24–29] **(Supplementary Figure 1F-G)**. To assess the extent to which the effects of genetic background on DEGs were controlled in the isogenic setting, we performed whole genome sequencing and identified 6,659 rare variants

(referred to as *secondary variants*) in the HD_01 line (see **Methods**). We classified these

secondary variants into distinct classes, including CNVs, simple tandem repeat (STR)

expansions, and SNVs within exonic, intronic, upstream, downstream, 5', and 3' UTR regions of

genes, as previously described[14,30], and found that 2%, 31%, 21%, and 10% of secondary

variants overlapped DEGs identified in iPSC, NPC, iMN, and MN, respectively **(Figure 2A,**

Supplementary Table 1). Rare noncoding intronic variants were also significantly associated

with altered usage of isoforms in genes without expression changes (**Figure 2A, Supplementary**

Table 1). Over-representation analysis of genes and isoforms with secondary variants revealed

significant enrichment for neurodevelopment, neuronal function, and signaling pathways such as

axon guidance, synaptic signaling, and PI3K-AKT signaling pathway (**Supplementary Figure**

1H, Supplementary Table 1). These results suggest that secondary variants, though individually

rare but collectively prevalent in healthy populations[31], can alter gene expression when combined

with the 16p12.1 deletion[32]. This observation also supports the idea that secondary variants may

exert latent effects that become unmasked in the context of the deletion[33,34].

Given the significant overlap between rare noncoding variants and DEGs (**Figure 2A**),

we evaluated their potential to alter chromatin accessibility. We identified six and 130 rare

noncoding variants that intersected with differentially accessible chromatin (i.e., differential

peaks or "Diffpeak") regions from ATAC-seq analysis of iPSCs and NPCs, respectively **(Figure**

2B, Supplementary Table 2). Motif enrichment analysis of these intersecting Diffpeak regions

revealed significant enrichment for binding motifs of TFs such as FOXA1, MYB, and TCF4,

which are involved in signaling pathways such as TGF-β, Wnt, and PI3K-AKT that are relevant

to neurodevelopment[35–38] (**Figure 2C, Supplementary Table 2)**. We also observed differential

expression of target genes affected by these noncoding secondary variants, such as *WWC1* and

TRIP13, which are likely involved in a broader regulatory network of those TFs (**Figure 2C**).

We next tested the combined effects of the 16p12.1 deletion and the secondary variants

using iPSC models derived from families with variable clinical features **(Figure 1C).** The DEGs

identified in deletion lines compared to nondeletion lines from these families were enriched for

genes associated with neurodevelopmental and psychiatric disorders; however, the enrichment

patterns varied by family (**Supplementary Figure 3A-B, Supplementary Table 8)**. We

analyzed each family separately and found that genes with secondary variants, including

MAPK10 and *SLC35A2*, showed significant changes in chromatin accessibility and gene

expression when both the deletion and secondary variant were present, suggesting potential

nonadditive effects. (**Figure 2C, Supplementary Figure 3C Supplementary Table 3).** This

phenomenon has been reported previously, where nonadditive functional effects were observed

among multiple schizophrenia-associated common variants in iPSC models[39,40]. Overall, our

findings support a modifier role for secondary variants, which act in combination with the

deletion, to shape gene expression patterns within neurodevelopmental pathways.

Figure 2. **Evaluating the impact of secondary variants on chromatin accessibility and gene**
expression in the context of 16p12.1 deletion. (**a**) Overlap between secondary variants and
DEGs (padj<0.05) or isoforms with altered usages (q<0.05) in the isogenic setting. Color

represents odds ratio from Fisher's exact test. *p<0.05, **Benjamini-Hochberg FDR<0.05,
Fisher's exact test. (**b**) Overlap between secondary variants and differential peaks obtained from
ATAC-seq (padj<0.01) in the isogenic setting. Color represents odds ratio from Fisher's exact
test. *p<0.05, **Benjamini-Hochberg FDR<0.05, Fisher's exact test. (**c**) Representative motifs
(left) of transcription factor binding sites enriched within ATAC-seq differential peak regions that
intersect with secondary variants. Examples (right) of altered chromatin accessibility peaks that
intersect with secondary variants as well as associated differential expression of the
corresponding gene in the isogenic and familial settings (transcripts per million, TPM, with
median values) at the NPC stages. ATAC-seq peaks were visualized using Integrative Genome
Viewer (IGV). From the DESeq2 results, the adjusted p-value (padj) for *WWC1* was 0.00041,
and for *TRIP13*, padj was 0.018 (**Supplementary Table 8**). Con, CRISPR control; Del, CRISPR
deletion; var, variant; DEL, deletion; SNV, single nucleotide variant; STR, short tandem repeat;
Del, 16p12.1 deletion lines; Nondel, nondeletion lines. Data in the familial setting were derived
from the GL_079 samples (**Supplementary Table 3**). For both RNA-seq and ATAC-seq, we
used n=3 independent experiments.

Variable neuronal phenotypes across genetic backgrounds

Beyond transcriptomic changes, we also evaluated the combined effects of the deletion and

secondary variants on neuronal phenotypes. At the NPC stage, we found no differences in

NESTIN and SOX2 levels between the deletion and nondeletion lines. However, we observed a

decrease in PAX6 (a dorsal telencephalic marker) (**Supplementary Figure 4 A-B**) and a highly

variable increase in NKX2.1 (a ventral telencephalic marker) in the deletion lines compared to

nondeletion lines (**Figure 3A**), suggesting altered neuronal lineage commitment during

differentiation. To further investigate this variability, we performed family-specific analysis

comparing the deletion lines to HD lines and, when available, to nondeletion lines from the same

family. We found a marked increase in NKX2.1-positive cells specifically in GL_007 and the

CRISPR deletion lines (**Figure 3A-B**). These results are consistent with previous findings in

other iPSC models of neurodevelopmental disorders[41]. In addition to NKX2.1, which is critical

for the development of inhibitory neurons, we examined VGAT, the vesicular GABA transporter,

in mature neurons expressing NeuN and MAP2 (**Supplementary Figure 4C**) and found

opposing trends across families, with a substantial increase in VGAT intensity in the deletion

lines of GL_007 and a variable decrease in the deletion lines of GL_077 and GL_079 compared

to controls (**Figure 3C-D**). We also assessed other genes involved in inhibitory neuron

differentiation and migration, including *DLX1*, *DLX2*, *LHX6* and *LHX8*, and found them to be

highly expressed across NPCs, iMNs, and MNs in both the CRISPR deletion and GL_007

deletion lines compared to controls (**Supplementary Figure 4D, Supplementary Tables 8**).

Although NKX2.1 level was elevated in the CRISPR deletion line compared to its isogenic

control, the absence of a significant difference in VGAT intensity suggests that this alteration

may not persist into the MN stage or may be too subtle to be detected with this assay.

Additionally, glutamatergic neuron production did not appear to be affected, as expression levels

of glutamatergic markers (*SLC17A6*, *SLC17A7*, *GRIN1*, *GRIN2B*, and *GLS*) were not

consistently altered across the deletion lines, and mature neurons showed no overt change in

VGLUT1 expression **(Supplementary Figure 4C)**. These results suggest that the deletion

contributes to altered production of inhibitory neurons under specific genetic backgrounds.

Aberrant neuronal proliferation and apoptosis, which alter the proportions of distinct

brain cell types, represent another convergent phenotype in neurodevelopmental disorders[42]. We

evaluated NPC proliferation by measuring EdU-labeled cells at 0, 24, and 48 hours, as well as

Ki-67-positive cells, and found no differences in proliferation rates between the deletion and

nondeletion lines **(Supplementary Figure 5A-B)**. Similarly, TUNEL assays revealed no

differences in apoptosis between the two groups **(Supplementary Figure 5C)**. However, when

grouped by family, we observed opposite trends in the deletion lines from GL_079 and GL_007

compared to controls: GL_079 deletion lines showed increased proliferation, while GL_007

deletion lines showed decreased proliferation and increased apoptosis compared to HD controls

(Figure 3E-F, Supplementary Figure 5D-G). GL_079 deletion lines also showed decreased

apoptosis, but only when compared to nondeletion lines from the same family **(Supplementary**

Figure 5F). Notably, these results correspond with the head-size phenotypes in P2C_079 and

FNC_079 from family GL_079 (macrocephaly) and P1C_007 from family GL_007

(microcephaly).

We also found evidence of altered developmental timing in deletion lines, a phenomenon

also reported in iPSC models of autism and schizophrenia[43,44]. A significant increase in TUBB3-

positive cells (a marker for newborn neurons) at the NPC stage was detected in the CRISPR

deletion and GL_007 deletion lines compared to controls **(Supplementary Figure 5H-J).** To

further investigate this trend, we performed weighted gene co-expression network analysis

(WGCNA) on RNA-seq data from NPC, iMN, and MN stages to identify gene modules

correlated with specific stages of differentiation and examine changes in these modules within

each family **(Supplementary Figure 6A, Supplementary Table 7)**. These gene modules were

enriched for differentiation stage-specific Gene Ontology (GO) terms such as cell division and

chemical synaptic transmission (**Supplementary Figure 6B**). The CRISPR deletion and GL_007

deletion lines exhibited significantly lower eigengene scores for the NPC-associated module

(*blue*) at the NPC stage and significantly higher eigengene scores for the mature neuron-

associated module (*turquoise*) at both the NPC and iMN stages (**Supplementary Figure 6C**).

These results suggest premature differentiation of NPCs. Furthermore, gene set enrichment

analysis (GSEA) comparing deletion lines to nondeletion lines from the isogenic setting and each

family across four differentiation stages revealed significant enrichment for GABAergic neuron

and DNA replication-related terms, as well as for signaling pathways associated with PI3K-AKT,

TGF-β, and Wnt (**Figure 3G, Supplementary Figure 6D, Supplementary Table 8).** Together,

these findings suggest that the combined effect of the deletion and secondary variants lead to

family-specific alterations in neurogenesis and associated signaling pathways.

Figure 3. Assessing neuronal phenotypes across genetic backgrounds. (a) Violin plot (left) with median values shows the percentage of NKX2.1-positive cells at the NPC stage in all deletion lines compared to all nondeletion lines. Bar plot (right) with mean values shows the percentage of NKX2.1-positive cells within family-specific lines. **(b)** Representative images of

NPCs stained for NKX2.1. Scale bars, 20 μm. **(c)** Bar plot with mean values shows VGAT fluorescence intensity normalized by MAP2 fluorescence intensity in each image. **(d)** Representative images of neurons stained for VGAT and MAP2. Scale bars, 20 μm. **(e)** Bar plot with mean values shows the percentage of Edu-positive cells in specific groups. **(f)** Representative images of EdU-labeled NPCs across three timepoints. Scale bars, 70 μm. **(g)** Waterfall plot of unbiasedly selected top pathways from each comparison of deletion versus nondeletion samples using GSEA (q<0.05) annotated in the Reactome, KEGG and WikiPathway (WP) (see **Methods**). NES, normalized enrichment score; isogenic, CRISPR deletion versus CRISPR control. Comparisons involve the grouped deletion carriers of each family versus the two healthy donor lines. The bold border indicates terms that belong to signaling pathways. Data are mean±s.e.m and two-tailed Welch's t-tests for **(a), (c), (e)**. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. n=3 independent experiments for each line, except for RNA-seq and downstream analyses where n=2 for iMNs and MNs of P1C_077, and MNs of HD_01. "n/a" indicates that Welch's t-tests were not performed due to high zero inflation. For **(a)** and **(c)**, n=6 images per experiment and for **(e)** n=8 images per experiment were quantified. For **(a)** and **(e)**, for GL_079, GL_077, GL_007, "c" contains all deletion lines and "nc" contains all nondeletion lines, for their respective families (see Figure 1C). For **(c)**, the same cell lines were used, excluding GMC_077 and GFNC_077 lines. In the family-based analyses, we compared deletion lines from GL_077 and GL_079 to both nondeletion lines within the same family and HD lines. For GL_007, due to the absence of nondeletion family lines, we compared the deletion lines to HD lines.

CRISPR activation of 16p12.1 genes reverses transcriptomic and neuronal defects

We previously found that the 16p12.1 genes exhibit diverse molecular functions and show

limited connectivity within a brain-specific co-expression network, especially when compared to

genes within the more penetrant 16p11.2 deletion[13,45,46]. Therefore, we sought to investigate the

role of individual 16p12.1 genes in driving distinct functional changes across genetic

backgrounds. We designed single-guide RNAs (sgRNAs) targeted to the promoters of *MOSMO*,

POLR3E, and *UQCRC2* and used CRISPR activation (dCas9-VP64 and MS2-P65-HSF1-

mediated CRISPRa[47]) to increase their expression in the deletion lines **(see Methods, Figure 4A,**

Supplementary Figure 7A). We selected these genes as they showed significantly reduced

expression in the deletion samples across neuronal differentiation cell states **(Supplementary**

Figure 2A). Previous studies have also implicated these genes in cellular functions such as Sonic

hedgehog (Shh) signaling, immune response, and mitochondrial homeostasis[48–50]. We performed

CRISPRa experiments at the iPSC stage in three proband lines to assess the contribution of

individual 16p12.1 genes to their more severe and varied cellular phenotypes and confirmed

sustained overexpression of the targeted genes in NPCs, the cell state in which most cellular

effects were observed in this study **(Supplementary Figure 7A)**. However, neurosphere

formation failed for CRISPRa of *MOSMO* in P2C_079. This could be potentially due to a

dosage-sensitive role of *MOSMO* in the genetic background of P2C_079 in regulating Shh

signaling[51,52], which is known to influence neurosphere formation[53].

Using RNA-seq in NPCs, we identified DEGs comparing each CRISPRa line to its

corresponding empty vector (EV) control. We found that most DEGs were unique to each

proband, with overlaps primarily within the same proband, rather than across different probands,

even when the same 16p12.1 deletion gene was activated **(Figure 4B, Supplementary Table 4)**.

Furthermore, CRISPRa of each one of these genes did not change the expression of other

16p12.1 genes **(Supplementary Figure 7B, Supplementary Table 4)**. These findings suggest

that CRISPRa-mediated restoration of 16p12.1 genes leads to outcomes modulated by the

genomic background and that these deletion genes are not strongly interconnected, consistent

with previous observations[46].

We investigated whether CRISPR activation of individual 16p12.1 genes could reverse

transcriptomic changes initially observed in probands with the deletion. By comparing DEGs

obtained from CRISPRa experiments with those from probands, we identified 5,058 genes with

opposing directions of gene expression change (i.e., reversed genes) **(Supplementary Figure**

7C, Supplementary Table 4). For example, restoring *POLR3E* reversed expression of 16 genes

across all probands, including cytoskeleton-related (*PLS3* and *LIMA1*), cell adhesion

(*PCDHA12*, *JAM2*, and *CD24*), and signaling transduction (*ZYX*, *S1PR1*, and *PDE1A*) genes

(Supplementary Figure 7D, Supplementary Table 4). Expression of specific phenotype-

related genes were also reversed by activating distinct 16p12.1 genes. For example, the epilepsy

risk gene *NNAT*[54] was upregulated in P2C_079 and P1C_007, who both have epilepsy, and was

reversed with CRISPRa of *POLR3E* in both probands. CRISPRa also reversed altered isoform

usage; activating *MOSMO* restored isoforms of *MECP2* (ENST00000627864) and *EPS8L2*

(ENST00000318562), genes that have been associated with autism and deafness, respectively, in

P1C_077, who manifested these clinical features **(Supplementary Table 4)**[55,56].

Next, we investigated whether CRISPR activation of the 16p12.1 genes rescued cellular

phenotypes. In P1C_007, overexpression of NKX2.1 was reversed with CRISPRa of *POLR3E*

and *MOSMO*, while proliferation and apoptosis phenotypes were rescued by CRISPRa of

UQCRC2 and *MOSMO* **(Figure 4C-D, Supplementary Figure 8A)**. Additionally,

overexpression of *UQCRC2* lead to further enhanced premature differentiation of NPCs to

neurons in this proband **(Supplementary Figure 8B)**. In P2C_079, CRISPRa of *POLR3E*
rescued hyperproliferation phenotypes **(Figure 4E, Supplementary Figure 8C)**. These results
underscore the direct role of 16p12.1 genes towards the neuronal defects observed in deletion
carriers, with some functional effects observed among multiple genes and others being gene
specific.
We further investigated the pathways altered by CRISPR activation of 16p12.1 genes and
found enrichment for multiple signaling pathways such as TGF-β**,** PI3K-AKT, Wnt, and MAPK
(Supplementary Figure 8D, Supplementary Table 4). Dysregulation of these pathways is
known to disrupt cell-fate determination and cell-cycle progression[57–59], as observed in the
deletion lines. Therefore, we performed GSEA on the genes with altered expression from
CRISPRa lines to assess the direction of change in associated signaling pathways compared to
EV controls in proband lines **(Figure 4F, Supplementary Table 4).** We found that CRISPRa of
POLR3E and *MOSMO* led to the restoration of TGF-β signaling, which corresponded to the
rescue of the NKX2-1 expression level in P1C_007. Furthermore, activation of *POLR3E* also
resulted in the upregulation of immune-related pathways, including interferon and cytokine
signaling, which were downregulated in multiple deletion lines**.** Specific genes within these
pathways, such as *STAT3* and *TGFB3* within immune pathways, and *FZD4*, *BMP7* and *NOG*
within Wnt and TGF-β pathways, were also found to be dysregulated in these probands,
potentially contributing to the reversal of proliferation and apoptosis phenotypes[60] **(Figure 4G)**.
Together, these results suggest that each 16p12.1 gene modulates distinct signaling cascades in a
genetic background-dependent manner, thereby contributing to variable functional trajectories
across individuals.

Figure 4. CRISPRa-mediated activation of 16p12.1 genes across probands (a) Schematic of
the CRISPRa approach (using dCas9-VP64 and MS2-P65-HSF1) in probands from the three
families. **(b)** Upset plot shows overlaps among DEGs (log$_2$|FC|≥0.5, padj<0.05) for each
comparison (CRISPRa sgRNAs of deletion genes vs. empty sgRNA-MS2 vector) in the three
proband lines. **(c)** Quantification and representative images of NKX2.1-positive cells with
CRISPR activation of 16p12.1 genes in NPCs from P1C_007. Scale bars, 20 μm. **(d)**
Quantification and representative images of Ki-67-positive cells with CRISPR activation of
16p12.1 genes in NPCs from P1C_007. Scale bars,70 μm. **(e)** Quantification and representative
images of Ki-67-positive cells with CRISPR activation of 16p12.1 genes in NPCs from
P2C_079. Scale bars, 70 μm. **(f)** Select pathways (q<0.05) enriched by GSEA across

comparisons of different sets of DEGs (q<0.05) annotated in the Reactome, WP, and KEGG
databases. Enrichment analysis with GSEA were made between DEGs obtained from deletion
NPCs versus controls compared to CRISPRa versus EV controls for each proband. NES,
normalized enrichment score; M, pathways derived from CRISPRa_*MOSMO* DEGs; P, pathways
derived from CRISPRa_*POLR3E* DEGs; U, pathways derived from CRISPRa *UQCRC2* DEGs.
White color fill indicates absence of terms in GSEA results. (**g**) Heatmap of normalized gene
expression in selected pathways (colored in (**f**)) across CRISPRa lines, clustering using Ward's
D2. Color scale represents z-scores calculated from TPM within each group. EV, empty sgRNA-
MS2 vector; M, CRISPRa of *MOSMO*; P, CRISPRa of *POLR3E*; U, CRISPRa of *UQCRC2*.
Data are mean±s.e.m and one-way ANOVA followed by Dunnett's post hoc test were used for
(**c**), (**d**), and (**e**). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. n=3 independent experiments
for each line, except for RNA-seq and downstream analyses where n=2 for iMNs and MNs of
P1C_077, and MNs of HD_01. For (**c**), (**d**), and (**e**), n=6 images per experiment were quantified.
376

Connectivity of genes with secondary variants in PPI network

To further investigate the role of secondary variants and explain phenotypic differences across

probands, we analyzed how genes with secondary variants whose expression was altered

following CRISPRa of individual 16p12.1 genes in NPCs, were connected within a protein-

protein interaction network[61] (**Figure 5A, Supplementary Figure 9A, Supplementary Table 5**).

In the *POLR3E* and *MOSMO* CRISPRa lines, we observed a higher network connectivity for

P1C_007 and P2C_079 compared to P1C_077, correlating with the presence of neuronal defects

in NPCs of P1C_007 and P2C_079 but not P1C_077 (**Figure 5A**). These findings were further

validated by analysis of PPI networks specifically within signaling pathways, which revealed

higher network connectivity in P1C_007 and P2C_079 (**Figure 5B**). Interestingly, in the

UQCRC2 CRISPRa lines, P1C_077 showed higher connectivity compared to P1C_007 and

P2C_079 (**Supplementary Figure 9A-B**). The highly connected nodes within this network

included proteins such as ADCY1, PDE4A, and GNG10, which are involved in cAMP signaling

and G protein signaling pathways that modulate synaptic functions in mature neurons[62,63]. This

may explain the absence of cellular phenotypes in P1C_077 at the NPC stage. These findings

indicate that the extent to which modifiers of individual 16p12.1 genes are connected within

signaling pathways is a determinant of phenotypic variation across probands.

Figure 5. **Connectivity of secondary variants across probands in response to CRISPR activation of 16p12.1 genes. (a)** Density plots show the connectivity (node degree, i.e., the number of connections a node has to other nodes in the network) of *POLR3E* and *MOSMO* CRISPRa DEGs (log$_2$|FC|>0.5, padj< 0.05) that overlap with secondary variants, as measured using the STRING database. Anderson-Darling k-sample test was used to calculate p values. **(b)** Visualization of the PPI network of DEGs (log$_2$|FC|≥0.5, padj<0.05) that overlap with secondary variants and were restored by CRISPRa of *POLR3E* in P1C_077 (top left), P1C_007 (top middle), and P2C_079 (top right), as well as by CRISPRa of *MOSMO* in P1C_077 (bottom left) and P1C_007 (bottom right). DEGs shown were selected based on their involvement in signaling pathways annotated in the Reactome database. p-value <10^{-16} for all networks. Protein nodes involved in specific pathways are color-coded based on annotations in the STRING database. Average node degrees and PPI enrichment p values were also calculated using the STRING database. n=3 independent experiments for each line.

Modulation of FOXG1 and JUN mediates phenotypic variability

We sought to identify functional convergence across samples through which the deletion confers

disease susceptibility, modulation of which by secondary variants lead to diverse outcomes. As

the network of genes within signaling pathways typically converge on TFs[64], we sought to

identify key TFs that regulate downstream effects in the deletion lines. We found that the

sequences within Diffpeak regions across the deletion NPCs were enriched for binding motifs of

TFs involved in developmental processes, such as FOS, HOXD13 and NR4A1[65–67]

(Supplementary Table 6). Furthermore, co-regulatory networks constructed from these TFs

whose binding motifs showed the most significant enrichment in Diffpeak regions across the

deletion lines identified FOXG1 and JUN as two of the top-ranked TFs using ChEA3 **(Figure**

6A, Supplementary Table 6, see **Methods).** Both of these TFs have been previously implicated

in multiple signaling pathways, including Wnt, BMP, and JNK[68–70]. Furthermore, we observed

altered expression of FOXG1 and JUN across the deletion lines compared to controls, along with

changes in both expression and chromatin accessibility of genes within their regulatory

networks. These included genes such as *HES1*, *KLF6*, *DLX2*, and *FZD8,* which are known to

play roles in neural processes such as inhibitory neuron production and NPC proliferation[71–74]

(Figure 6A, Supplementary Fig. 10A-B, Supplementary Table 6). Therefore, we hypothesized

that the 16p12.1 deletion affects regulatory hubs within signaling pathway interaction networks,

and that modulating the expression of individual 16p12.1 genes would, in turn, alter the

expression of these hub genes, such as FOXG1 and JUN, as well as their connected genes,

leading to changes in cellular phenotypes (**Figure 7**). To test this, we further investigated the

roles of FOXG1 and JUN towards the observed cellular dysregulations in the deletion lines.

Since altered activity of the TFs reflects perturbations across multiple associated signaling

pathways, we did not expect a direct one-to-one correspondence between specific TF activity and

cellular phenotypes. We found that the expression levels of FOXG1 and JUN varied across

probands, and these levels were differentially modulated with CRISPR activation of different

16p12.1 genes **(Figure 6B-C)**. Changes in FOXG1 and JUN expression in the P1C_007

CRISPRa lines, and changes in JUN expression in the P2C_079 lines, were observed alongside

the reversal of cellular phenotypes upon CRISPR activation **(Figure 4, Figure 6D)**. Furthermore,

we found that the expression of genes within their regulatory networks, including *DLX2* and

KLF6, mirrored changes in *FOXG1* and *JUN* expression across CRISPRa lines **(Figure 6E)**.

These findings suggest that key TFs and the regulatory network within individual 16p12.1 gene-

associated signaling pathways mediate the phenotypic trajectories of the deletion (**Figure 7**).

Figure 6. Modulation of gene regulatory hubs corresponding with variable phenotypes. (a) TF co-regulatory network constructed by ChEA3 using TFs whose binding motifs were most significantly enriched in ATAC-seq Diffpeak regions from comparison of deletion lines vs. healthy donor lines at the NPC stage. Motif lists are provided in **Supplementary Table 6** (see **Methods**). The panel below depicts IGV snapshots of ATAC-seq peaks showing increased (*DLX2*) or decreased (*KLF6*) chromatin accessibility for select genes in the regulatory network of FOXG1 and JUN, respectively. **(b)** Quantification and representative images of FOXG1-positive NPCs in CRISPR activated lines from P1C_077, P1C_007, and P2C_079. Scale bars, 20 μm. EV, empty sgRNA-MS2 vector; M, CRISPRa of *MOSMO*; P, CRISPRa of *POLR3E*; U, CRISPRa of *UQCRC2*. **(c)** Quantification and representative images of JUN-positive NPCs in CRISPR activated lines from P1C_077, P1C_007, and P2C_079. Scale bars, 20 μm. **(d)** Overview of CRISPRa results at the NPC stage. Columns represent CRISPRa lines from the three probands; rows indicate the direction of change based on phenotype quantification. Empty

bubbles denote no detectable change. Rescue of cellular phenotype refers to the reversal of a cellular phenotype observed in the proband lines (compared to healthy donor controls). The phenotypes of proliferation, apoptosis, inhibitory neuron, and premature maturation were, respectively, measured with EdU, TUNEL assay, VGAT, NKX2.1 and TUBB3 positive cells. **(e)** Representative heatmap of normalized expression of genes within the regulatory networks (identified using ChEA3) of FOXG1 (left) and JUN (right) across the CRISPRa lines. Color scale represents the z-scores calculated from TPM within each group. Data are mean±s.e.m and one-way ANOVA followed by Dunnett's post hoc test for **(b)** and **(c)**. *$p<0.05$; **$p<0.01$; ***$p<0.001$; ****$p<0.0001$. n=3 independent experiments for each line. 6 images per experiment were quantified for **(b)** and **(c)**.

Figure 7

Figure 7. Conceptual model illustrating how the interplay between the 16p12.1 deletion and secondary variants contributes to variable expressivity. The interactive effects are mediated through regulatory hubs, such as TFs (e.g., FOXG1, JUN), within signaling pathways. The network is colored for the TF regulatory hub, and two-toned colors indicate genes shared among multiple pathways. Patient-specific secondary variants or combinations of variants lead to distinct phenotypic trajectories, shown by the red or blue connecting lines traversing distinct genetic pathways.

DISCUSSION

Our study provides a framework to understand how variable expressivity in neurodevelopmental disorders arises from the complex interplay between disease-associated variants and secondary variants in the genetic background. Using the 16p12.1 deletion as a model, we found that primary and secondary variants jointly modulate key signaling pathways and shape distinct phenotypic trajectories through transcription factors within gene regulatory networks (**Figure 7**). Several themes have emerged from our work, contributing to the emerging picture that network-level genetic interactions underlie variable expressivity in complex genetic disorders.

Previous studies have linked CNVs to changes in chromatin accessibility and gene expression in neurodevelopmental disorders[75,76]. Here, we observed potential nonadditive effects of primary and secondary variants on both chromatin accessibility and gene expression. Notably, even the ostensibly healthy control used to generate the CRISPR deletion line did not fully control the genetic background effects and therefore cannot isolate the effect of the deletion alone. The presence of secondary variants interacting with the deletion highlights the need to carefully account for genetic background effects in future studies, even when using isogenic models, as introducing the same variant into distinct lines may yield different results when characterizing variant function.

Although observed within specific genetic backgrounds, the 16p12.1 deletion led to defects in inhibitory neuron production, abnormal cell proliferation and apoptosis, and premature neuronal differentiation. These findings reflect disruptions in excitatory/inhibitory balance, neurogenesis dynamics, resulting in altered cell type proportions during brain development, a hallmark of multiple neurodevelopmental disorders including ASD, schizophrenia and intellectual disability[19,41,77]. Furthermore, CRISPRa-based rescue of 16p12.1 genes supports our previous findings[46] that each gene within this region functions independently, as rescue of different genes reversed distinct sets of dysregulated genes and cellular phenotypes without affecting the expression of other deleted genes. Future work using this framework could incorporate CRISPR interference-based gene knockdown and be extended to other variably expressive CNVs, such as those at 1q21.1, 15q13.3, 16p11.2, and 22q11.2, to link genes within these regions to cellular phenotypes across the diverse genetic backgrounds of individual patients.

We observed alterations across multiple signaling pathways, including Wnt, TGF-β,

PI3K-AKT, and immune-related pathways, several of which have been implicated in

neurodevelopmental disorders[58,78–81]. These findings reflect the extensive crosstalk and network-

level interconnectivity among these pathways[78]. Furthermore, we found that the severity of

phenotypic outcomes correlated with the PPI connectivity of secondary variants in specific

signaling pathways. In addition, consistent with prior studies identifying convergent mechanisms

underlying heterogeneity in autism[82], we found differential modulation of transcription factors

such as FOXG1 and JUN, which serve as regulatory hubs across deletion lines with distinct

genetic backgrounds. TFs have been shown to be key regulators of cellular differentiation, and

their dysregulation has been linked to developmental disorders, including craniofacial

anomalies[83]. Together, these results underscore the importance of examining both inter-

individual variability and the convergent mechanisms that emerge across diverse genetic

contexts.

While our study provides key insights into the functional impact of secondary variants,

several aspects could be further refined or expanded in future work. *First*, while we observed

strong associations between secondary variants and changes in gene expression and chromatin

accessibility, the small sample size limits our ability to infer causality without further

experimental validation. High-throughput approaches such as Perturb-seq and CROP-seq could

help confirm these interactions and elucidate how they modulate signaling pathways[84,85]. *Second*,

we used 2D iPSC differentiation combined with bulk RNA-seq, which may overlook cell type–

specific effects, particularly in neuronal subtypes and non-neuronal brain cells relevant to

neurodevelopmental disorders[38]. Future work could leverage advanced models such as neural

organoids, assembloids, chimeroids, or other emerging platforms, which provide greater cellular

diversity and spatial resolution[86]. Overall, our findings lay the groundwork for future functional

studies to explore genotype–phenotype relationships, inter-individual variability, and potential

personalized therapeutic strategies.

In summary, our study provides a framework for understanding how the combined effects

of disease-associated variants and genetic background drive variable expressivity in

neurodevelopmental disorders. By uncovering both shared and background-specific impacts on

gene regulation and signaling pathways, we underscore the importance of accounting for genetic

context in functional studies and in developing personalized therapeutic strategies.

Supplementary Figure 1. Generation of CRISPR/Cas9-mediated 16p12.1 deletion. (a)
CRISPR/Cas9 strategy for generating 16p12.1 deletion. Arrows demonstrate the locations of the
designed sgRNAs. The engineered 465-kbp deletion was validated by Sanger sequencing. **(b)**
Confirmation of the deletion by SNP array. **(c)** Representative images of the CRISPR edited line
stained for pluripotency markers (SOX2, SSEA4, NANOG and OCT4). Scale bars, 70 μm. **(d)**
Volcano plots show the differential expression of 16p12.1 deletion genes (*UQCRC2*, *MOSMO*,
VWA3A, *EEF2K*, *POLR3E* and *CDR2*) in the isogenic setting across neuronal differentiation
stages (iPSC, NPC, IMN and MN). Dashed lines represent the threshold ($\log_2$|FC|≥0.5,

padj<0.05). Red, upregulated genes; blue, downregulated genes; grey, non-significant genes. Deletion genes that are not labeled demonstrate extremely low expression levels and were not detected. **(e)** IGV snapshots show the ATAC-seq peaks of chromatin accessibility within the 16p12.1 deletion region from the CRISPR-edited line. **(f)** Enrichment analysis of DEGs ($\log_2|FC|\geq1$, padj <0.05) obtained from RNA-seq of the CRISPR-edited line compared to isogenic controls queried within published datasets. Gene lists from selected papers are provided in **Supplementary Table 8**. **(g)** Enrichment analysis of DEGs ($\log_2|FC|\geq1$, padj <0.05) obtained from RNA-seq of the CRISPR-edited line compared to isogenic controls within DisGeNET. For **(f)** and **(g)**, Fisher's exact test, bold black circles indicate p<0.05, bold red circles indicate Benjamini-Hochberg FDR<0.05. **(h)** Waterfall plot shows enrichment of DEGs overlapping secondary variants across the 4 neuronal differentiation stages. Top 30 terms (q<0.05) were unbiasedly selected from GO (Biological Process, Gene Ontology), KEGG (Kyoto Encyclopedia of Genes and Genomes) and Reactome databases. RNA-seq and downstream analyses: n=3 independent experiments; ATAC-seq and downstream analyses: n=3 independent experiments.

568
569
Supplementary Figure 2. Validation of cell identities across stages of neuronal
differentiation. **(a)** Volcano plots show the differential expression of 16p12.1 deletion genes
(*UQCRC2*, *MOSMO*, *VWA3A*, *EEF2K*, *POLR3E* and *CDR2*) comparing all the deletion lines to
nondeletion lines across neuronal differentiation stages (iPSC, NPC, IMN and MN). Dashed
lines represent the statistical threshold for significance (log2|FC|≥0.5, padj<0.05). Red,
upregulated genes; blue, downregulated genes; grey, non-significant genes. Deletion genes that
are not labeled demonstrate extremely low expression levels and were not detected. **(b)** Volcano
plots show the differential peaks in 16p12.1 deletion when comparing all the deletion lines to
nondeletion lines at iPSC and NPC stages. Dashed lines represent the threshold (padj<0.01).
Red, upregulated peaks; blue, downregulated peaks; grey, non-significant peaks. Black dots
demonstrate differential peaks within 16p12.1 regions. A list of all ATAC-seq peak regions is
provided in **Supplementary Table 2**. **(c)** Line plot shows the expression of select marker genes
with shading representing 95% confidence interval of the mean across all the lines and
differentiation stages. Y-axis represents z-scores of TPM. iPSC markers: SOX2, POU5F1, and
FUT4; NPC markers: SOX2, HES1, NES, and EMX2; neuron markers: MAP2, DLG4, NCAM1,
and RBFOX3. **(d)** IGV snapshots show the ATAC-seq peaks of chromatin accessibility from
HD_01 and HD_02 in the 16p12.1 deletion regions. For RNA-seq, ATAC-seq and downstream
analyses: n=3 independent experiments, except for RNA-seq and downstream analyses where
n=2 for iMNs and MNs of P1C_077, and MNs of HD_01.

Supplementary Figure 3. Family-specific effects on gene expression. (a) Enrichment of DEGs
(log$_2$|FC|≥1, padj <0.05) from deletion versus nondeletion within-family comparisons in
published datasets. A complete list of genes from select papers is provided in **Supplementary
Table 8**. **(b)** Enrichment analysis of DEGs (log$_2$|FC|≥1, padj <0.05) from deletion versus
nondeletion within-family comparisons in DisGeNET. For **(a)** and **(b)**, Fisher's exact test, bold
black circles indicate p<0.05, bold red circles indicate Benjamini-Hochberg FDR<0.05. GL_007
carriers are MC_077 and P1C_077, noncarriers are FNC_007 and S2NC_077, and GL_079
carriers are MC_079 and P2C_079, noncarriers are FNC_079 and S2NC_079. **(c)** In the same
family, examples of genes and isoforms overlapping with secondary variants showing altered
(TPM and mean values) gene expression at iMN and MN stages (**Supplementary Table 3**).
*indicates the carriers of secondary variants. SNV, single nucleotide variant; STR, short tandem
repeat; Del, 16p12. 1 deletion lines; Nondel, nondeletion lines. Two-way ANOVA tests for all the
examples using TPM are interaction p<0.05. For RNA-seq and downstream analyses: n=3
independent experiments, except for iMNs and MNs of P1C_077, where n=2.

Supplementary Figure 4. Characterization of NPCs and neuronal lineage markers. (a) Violin plots show the percentage of NPCs that were positive for NESTIN, SOX2, PAX6 and quantification of VGAT staining in neurons from all deletion lines versus all nondeletion lines. The embedded box plot indicates the interquartile range (IQR) and median (black horizontal line). p-values calculated using two-tailed Welch's t-test. **(b)** Representative images of NPCs stained for NESTIN, SOX2, and PAX6. **(c)** Representative images (left) of MNs stained for NeuN and MAP2 (mature neuron markers) and VGLUT (excitatory neuron marker), and volcano plots (right) showing the differential expression of five marker genes for glutamatergic neurons between deletion lines in each family and healthy donor lines, as well as the CRISPR deletion compared to the CRISPR control. Red, upregulated genes; blue, downregulated genes; grey, non-significant genes. **(d)** Heatmap shows the expression levels of inhibitory neuron-related genes across neuronal differentiation stages. Note that the differences in gene expression between the CRISPR-edited line and controls become more subtle as neuronal differentiation progresses (from iPSC to MN). Color scale represents $\log_2(\text{TPM}+1)$. RNA-seq and downstream analyses: n=3 independent experiments, except for MNs of HD_01, where n=2, and iM and MNs of P1C077, where n=2. Scale bars for **(b)** and **(d)**, 20 μm.

Supplementary Figure 5. Altered proliferation, apoptosis, and neuronal maturation at the NPC stage. (a) Violin plot shows the percentage of EdU-positive cells at the NPC stage in all deletion lines versus all nondeletion lines across three time points. The embedded box plot indicates the interquartile range (IQR) and median (black horizontal line). **(b)** Violin plot shows the percentage of Ki-67 positive cells at the NPC stage in all the deletion lines versus all the nondeletion lines. The embedded box plot indicates the IQR and median (black horizontal line). **(c)** Violin plot shows the percentage of TUNEL-positive cells at the NPC stage in all the deletion lines versus all the nondeletion lines. The embedded box plot indicates the interquartile range (IQR) and median (black horizontal line). **(d)** Representative images of NPCs stained for Ki-67. Scale bars, 70 μm. **(e)** Bar plot (with mean values) shows the percentage of Ki-67-positive cells in different samples. **(f)** Bar plot shows the percentage of TUNEL-positive cells in different samples. **(g)** Representative images of TUNEL-labeled NPCs. Scale bars, 70 μm. **(h)** Violin plot shows the percentage of TUBB3-positive cells at the NPC stage in all the deletion lines versus all the nondeletion lines. The embedded box plot indicates the interquartile range (IQR) and median (black horizontal line). **(i)** Bar plot shows the percentage of TUBB3- positive cells in different samples. **(j)** Representative images of TUBB3-positive NPCs. Scale bars, 20 μm. CRISPR_del, CRISPR deletion; CRISPR_con, CRISPR control; GL_077_c, 16p12.1 deletion lines in GL_077 (GMC_077, MC_077, P1C_077); GL_077_nc, nondeletion lines in GL_077 (GFNC_077, FNC_077, S2NC_077); GL_079_c, deletion lines in GL_077 (MC_079, P2C_079); GL_079_nc (FNC_079, S2NC_079); GL_007_c (M1C_007, P1C_007); HD, healthy donor lines (HD_01, HD_02). Two-tailed Welch's t-test, *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001, for **(a)**, **(b)**, **(c)**, **(e)**, **(f)**, **(h)**, **(i)**. n=3 independent experiments for each line. 6 images per experiment were quantified.

Supplementary Figure 6. Transcriptome dynamics during neuronal differentiation. (a) Heatmap shows Pearson's correlation coefficients between WGCNA modules and differentiation stages. Student asymptotic p-value for correlation for statistics of Pearson correlation. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Color bar represents direction and strength of correlation. **(b)** GO term enrichment of genes in each module. **(c)** Box plots show the eigengene scores across the differentiation stages. Two-tailed Welch's t-test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Each box shows the IQR, with a horizontal line indicating the median. **(d)** Waterfall plot of total unbiasedly selected top 100 pathways enriched for the DEGs identified across differentiation stages comparing deletion to nondeletion lines in GL_077 and GL_079 by GSEA (q<0.05) annotated in Reactome, KEGG and WP (WikiPathway) databases. The bold

672   border indicates terms that belong to signaling pathways. NES, normalized enrichment score;
673   GL_077, GMC_077, MC_077, and P1C_077 versus GFNC_077, FNC_077, and S2NC_077;
674   GL_079, MC_079, and P2C_079 versus FNC_079 and S2NC_079. n=3 independent
675   experiments, except for RNA-seq and downstream analyses where n=2 for iMNs and MNs of
676   P1C_077, and MNs of HD_01.
677
678

a

RT-qPCR of 16p12.1 genes in distinct CRISPRa lines

b

c Overlapped proband vs healthy donor and CRISPRa rescue vs EV DEGs

d Reversed DEGs overlapping across probands

Supplementary Figure 7. Transcriptomic alterations induced by CRISPRa-mediated activation of individual 16p12.1 genes. (a) Bar plot shows relative mRNA expression levels of *MOSMO*, *POLR3E*, and *UQCRC2* across CRISPRa lines derived from the three probands (P1C_077, P2C_079, and P1C_007), measured by RT-qPCR. Each bar represents the mean±standard error of three independent experiments. **(b)** Volcano plots show the differential expression of 16p12.1 deletion genes (*UQCRC2*, *MOSMO*, *VWA3A*, *EEF2K*, *POLR3E*, and *CDR2*) comparing CRISPRa of individual 16p12.1 genes to EV lines. Dashed lines represent the statistical significance threshold ($\log_2|FC|\geq0.5$, padj<0.05). Red, upregulated genes; blue, downregulated genes; grey, non-significant genes. Deletion genes that are not labeled demonstrate extremely low expression levels and were not detected. **(c)** Venn diagrams show the overlaps (reversed DEGs) of DEGs (probands with the deletion versus HDs) and DEGs (padj<0.05) from CRISPRa of individual genes versus EV in the proband lines. Gene lists are provided in **Supplementary Table 4**. **(d)** Venn diagrams show the patterns of all DEGs that were reversed by CRISPR activation of each 16p12.1 gene across probands. Gene lists are provided in **Supplementary Table 4**. Up_to_down, upregulated in deletion lines but downregulated by CRISPRa; down_to_up, downregulated in deletion lines but upregulated by CRISPRa; HD, healthy donors (HD_01 and HD_02); EV, empty sgRNA-MS2 vector.

Supplementary Figure 8. Alterations in cellular phenotypes following CRISPR activation of 16p12.1 genes. **(a)** Quantification and representative images of TUNEL-labeled NPCs in CRISPR activated lines from P1C_007. Scale bars, 70 μm. **(b)** Quantification and representative images of NPCs stained for TUBB3 in CRISPR activated lines from P1C_007. Scale bars, 20 μm. **(c)** Quantification and representative images of TUNEL-labeled NPCs in CRISPR activated lines from P2C_079. Scale bars, 70 μm. **(d)** Plots show enrichment of downregulated (left, blue) and upregulated (right, red) DEGs within signaling pathways (log$_2$|FC|≥0.5, padj <0.05) obtained from RNA-seq of CRISPR activated versus EV lines in probands (M: *MOSMO*; P: *POLR3E*, and U: *UQCRC2*). The size of the circles represents gene counts within each pathway, and the color intensity corresponds to significance of enrichment. Data are mean±s.e.m and one-way ANOVA followed by Dunnett's post hoc test, *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001, for **(a)**, **(b)**, and **(c)**. EV, empty sgRNA-MS2 vector.

Supplementary Figure 9. Connectivity of secondary variants in response to CRISPR

activation of *UQCRC2* within protein-protein interaction networks. (a) Density plots show

the connectivity (node degree) of DEGs that overlap with secondary variants ($\log_2|FC|\geq0.5$,

padj<0.05) and are reversed with CRISPR activation of *UQCRC2* in three probands, as measured

using the STRING database. Anderson-Darling k-sample tests were used to calculate p-values.

(b) PPI network of DEGs ($\log_2|FC|\geq0.5$, padj<0.05) involved in signaling pathways (from

Reactome database) that overlap with secondary variants and were reversed by CRISPRa in the

probands. For all networks, $p<10^{-16}$. Protein nodes involved in specific pathways were differently

colored using the STRING database. Average node degrees and PPI enrichment p values were

also calculated using the STRING database.

Supplementary Figure 10. Expression changes of *FOXG1*, *JUN* and their regulatory network genes in NPCs. (a) Bar plots with mean values show the TPM of gene expression for *FOXG1* and *JUN* across the proband lines (bottom panel). One-way ANOVA followed by Dunnett's post hoc test. **(b)** Venn diagrams show the overlap of genes from DEGs (log2|FC|≥0.5, padj<0.05), ATAC-seq (padj<0.01), and genes within regulatory networks of FOXG1 and JUN as predicted by ChEA3 based on DEGs. Select example genes are also labeled. GL_077 carriers (GMC_077, MC_077 and P1C_077); GL_079 carriers (MC_079 and P2C_079); GL_007 carriers (M1C_07 and P1C_07); healthy donor (HD_01 and HD_02). n=3 independent experiments.

MATERIALS AND METHODS

Patient recruitment and clinical phenotype analysis.

Patient recruitment and clinical phenotyping were performed as previously described[14]. Families were recruited through clinics by obtaining de-identified samples and clinical data based on an approved protocol (IRB #STUDY00017269). Detailed medical histories, including clinician-reported, guardian-reported (for children), or self-reported (for adults), were collected, and standardized questionnaires were administered to assess developmental phenotypes in children and psychiatric features in adults. Questionnaires for children assessed neuropsychiatric and developmental features, anthropometric measurements, congenital anomalies in multiple organ systems, and family history of medical or psychiatric conditions. For assessing quantitative phenotypes, we conducted quantitative assessment using the Hansen Research Services Matrix Adaptive Test (HRS-MAT)[87] to evaluate nonverbal IQ and the Social Responsiveness Scale (SRS)[88] to assess autism-related social behavior. HRS-MAT was self-administered by participants via an online platform. SRS was delivered through a RedCap-based survey platform maintained by the Geisinger Autism and Developmental Medicine Institute. For participants aged 18 or older, the SRS was self-reported; for those under 18, responses were provided by parents or guardians. Body Mass Index (BMI) and head circumference were obtained either from medical records or self/guardian-reports. BMI was calculated from height and weight data obtained from medical records or self/guardian-reports where necessary. Both BMI and head circumference were converted to age- and sex-adjusted z- scores. For the assessment of developmental milestones, we followed the CDC guidelines[89]. For detailed phenotypic data and related information, please contact the corresponding author.

Induced pluripotent stem cell reprogramming and maintenance

Induced pluripotent stem cells (iPSCs) were reprogrammed from peripheral blood mononuclear cells using the Cytotune-iPS 2.0 Sendai Programing kit, including the four Yamanaka reprogramming factors POU5F1 (OCT4), SOX2, KLF4, and MYC (ThermoFisher Scientific) as described previously[90], and validated by flow cytometry (EPCAM, TRA-1-81, SSEA4 and CD9) and immunofluorescence (NANOG, OCT4, SOX2 and SSEA4). HD_01 and HD_02 were derived from CD34+ cord blood from healthy male and female donors, respectively (BID00274 and BID00271, NINDS). These lines were grown in mTESR1 (#85850 StemCell Technologies)

or mTESR plus medium (#100-0276 StemCell Technologies), supplemented with 1%

Penicillin/Streptomycin (# P4333 Sigma-Aldrich) on dishes coated with Geltrex (#A1413302

Gibco), and were passaged using 0.5mM EDTA (#AM9260G Invitrogen) or ReLeSR (#100-

0483, StemCell Technologies), with Rock inhibitor (Y-27632) to improve cell survival (# 72304

StemCell Technologies). Cells were incubated at 37ºC and 5% CO_2. Mycoplasma tests were

performed on iPSCs and NPCs using mycoplasma PCR detection kit (#MP0035, Sigma-

Aldrich).

Generation of CRISPR/Cas9-mediated 16p12.1 deletion iPSC line.

The sequences of two sgRNAs are: (1) TCGGTGCTTAGGATCAGCCT, (2)

GCCACTAGCTGACATGGTTG. Two separate vectors were used for delivering the sgRNAs:

pSpCas9(BB)-2A-Puro (PX459) V2.0 was a gift from Feng Zhang (Addgene plasmid # 62988)

and pGH020_sgRNA_G418-GFP was a gift from Michael Bassik (Addgene plasmid # 85405).

Two vectors with sgRNAs were transfected into the HD_01 line using Lipofectamine stem

transfection reagent (# STEM00001, Invitrogen), and the CRISPR control line was generated via

transfection of empty vectors. Puromycin selection (0.5ng/ml) was performed 24 hours after

transfection and lasted an additional 24 hours before the selection medium was replaced with

mTESR1 medium. The cells recovered for several days before being diluted and split into 96-

well plates manually to isolate single-cell clones. Each clone was cultured for two weeks and

genotyped by the following two set of primers: WT-F: GACTTCCTCCACATCTTCCTCTA,

WT-R: TCAAATAGAGGGGCAGGAGC (546bp); Deletion-F:

TCCTCAGACTCAATAATTGCCA, Deletion-R: TGACCTTTACTCTGTGACATTGC (942bp).

The desired PCR products were purified, and sanger sequencing was used to confirm that the

correct sequence was present. For further conformation, genomic DNA of the selected clones

was extracted by GenElute Mammalian Genomic DNA Miniprep kits (#G1N350, Sigma-

Aldrich) and PureLink Genomic DNA Mini kit (#K182001, Invitrogen) for SNP-array.

RNA isolation and RT-qPCR

Total RNA was isolated using the TRIzol reagent (#15596026, Invitrogen) and PureLink RNA

mini kit (#12183018A, invitrogen), following a modified version of this kit's protocol. Cells

were collected directly in TRIzol and frozen until RNA extraction. Chloroform was added to the

TRIzol in a 1:5 ratio, shaken vigorously for 30 seconds, then incubated for 3 minutes before

being centrifuged at 12,500 g for 15 minutes at 4°C. The upper phase was collected in a fresh

tube and an equal amount of ethanol was added before vortexing. The mixed reagent was

transferred to a spin column, and washing and recovery steps proceeded as described in the kit

protocol. Isolated RNA was treated with TURBO DNase (catalog #AM1907, Thermo Fisher

scientific, MA, USA). RT-qPCR was performed in three independent experiments, each with

three replicates, for each sample. 1000ng RNA was used in reverse transcription reaction by

qScript cDNA Synthesis Kit (Quantabio, catalog#95047-100). The cDNA product was diluted

100 times and 2ul cDNA was used in 10ul RT-qPCR reaction, using PowerTrack SYBR Green

Master Mix (catalog#A46109, Applied Biosystems). RT-qPCR was performed using the

QuantStudio 3 (Applied Biosystems) through the following steps: initial denaturation step at

95 °C for 2 min, followed by 40 cycles of denaturation at 95 °C for 15 s and

annealing/elongation at 60°C for 1 min. A melt curve analysis was conducted at the end of the

amplification. The results were analyzed using QuantStudio Design & Analysis software. The

following primers were used: GAPDH-F: ATGGGGAAGGTGAAGGTCGG, GAPDH-R:

TGACGGTGCCATGGAATTTG; POLR3E-F: GGAGCAGATTGCGCTGAA, POLR3E-R:

TTACTGGTGGTCTGGGAAGA; UQCRC2-F: TTCAGCAATTTAGGAACCACCC;

UQCRC2-R: GGTCACACTTAATTTGCCACCAA; MOSMO-F:

CTGTCACATGTGGTTTGCTGG; MOSMO-R: GGGCAGCCATACAGAAAAGGA.

Neural conversion of iPSCs to NPCs

The neural conversion of iPSCs was performed as previously described with modifications[18]. On

day 0, iPSCs were treated with Collagenase Type IV (StemCell Technologies #07909). Then,

cells were scraped and transferred to an uncoated 60mm dish with mTESR1 media supplied with

10uM Y-27632 for embryoid body (EB) formation. After 48 hours in suspension, mTESR1

media was switched to neural differentiation media (N2 media) containing DMEM/F-12

(catalog# 10565018, Gibco) with 1% N-2 Supplement (catalog#17502001, Gibco) and 1% MEM

Nonessential amino acids (catalog#11140050, Gibco), 2ug/ml Heparin (catalog#07980, StemCell

Technologies), 1% Penicillin/Streptomycin (catalog#P4333, Sigma), 5uM SB431542

(catalog#72232, StemCell Technologies) and 0.25uM LDN193189 (catalog#72147, stem cell

technologies). The EBs were cultured in neural differentiation media for 4 days and the media

was changed every two days. On day 6, EBs were seeded on Geltrex-coated plates for 8 days to

form rosettes. From days 6- 8, rosettes were cultured in N2 media without Dual-SMAD

inhibitors, and from days 8- 14, they were cultured in N2B27 media containing 1:1 DMEM/F-12

and Neurobasal Medium (catalog#21103049, Gibco) with GlutaMax supplement

(catalog#35050061, Gibco), 1% N-2 Supplement, 2% B-27 supplement minus vitamin A

(catalog#12587010, Gibco), 1% MEM Nonessential amino acids, 2ug/ml Heparin, 1%

Penicillin/Streptomycin. On day 14, rosettes were treated with Collagenase Type IV and then

transferred to uncoated 60mm dish with N2B27 media for neurosphere formation in suspension

culture for 12 days. On day 26, neurospheres were dissociated by Accutase (catalog#A1110501,

Gibco) then plated on Geltrex-coated plates. Neural progenitor cells were maintained in Stemdiff

neural progenitor medium (catalog#05833, StemCell Technologies) and passaged 1:2-1:3 using

Accutase. This protocol is expected to create a population of NPCs which express SOX2 and

NESTIN, with the majority of cells expressing Pax6.

Neuronal differentiation of NPCs to neurons

Plates were prepared for neuronal differentiation with Poly-D-Lysine (PDL, catalog#A3890401,

Gibco) and Laminin (catalog#L2020, Sigma-Aldrich). PDL was diluted 1:1 with PBS to a

concentration of 50ug/ml and left in the wells for 1 hour at room temperature. PDL was aspirated

and the well was washed 4-5 times with sterile DI water and then allowed to dry for 15 minutes.

Laminin was diluted to 20ug/ml in chilled dPBS and added to the wells. After characterization,

NPCs were plated 800,000 cells/per well on the 6-well plates. The next day, 0.2uM Compound E

(catalog#73952, StemCell Technologies) was added to the media. In the first two weeks,

neuronal differentiation media was used, containing Neurobasal medium, 1% GlutaMAX, 1%

Penicillin/Streptomycin, 1% N-2 Supplement, 2% B-27 supplement (#17504044, Gibco), 0.2%

MycoZap Plus-PR (catalog#195263, LONZA) supplied with 20ng/ml BDNF (#450-02-1mg,

Pepro Tech), 20ng/ml GDNF (450-10-1mg, Pepro Tech), 200uM Ascorbic acid(#72132,

StemCell Technologies), 1uM cAMP (#A9501) and 1ug/ml Laminin. In the last two weeks, the

neuronal differentiation media was switched to BrainPhys Neuronal medium (catalog#05790,

StemCell Techonologies), supplemented with 40uM 5-Fluoro-2′-deoxyuridine (FUDR)

(catalog#F0503, Sigma-Aldrich) to kill mitotic cells. Half media changes were performed every

3 days.

Cell proliferation and apoptosis

Proliferation and apoptosis assays were adapted from a previous study[18]. On day 0, NPCs at

passage 6 were seeded at $1x10^5$ on 18mm diameter coverslips coated in PDL (1:1 in PBS) and

Geltrex (1:100 in DMEM/F12) on 12-well cell culture plates in neuronal differentiation medium

containing Neurobasal media, 1% N-2 supplement, 2% B-27 supplement minus vitamin A, 1%

GlutaMax, 1% Penicillin/Streptomycin, and were incubated overnight. On the morning of day 1,

neural progenitor cells were treated with 10uM 5- ethynyl-2'-deoxyuridine (EdU)

(catalogC10337, Invitrogen) for four hours and before the media was replaced with fresh

medium without Edu. Coverslips were collected and fixed at three timepoints, of no chase (0

hours), 24-hour chase, and 48-hour chase. The Edu label was detected via Click-iT chemistry

following manufacturers' instructions. At the 24-hour chase timepoint, coverslips were also

stained for Ki-67 markers (1:200 catalog#12202, Cell Signaling TECHNOLOGY). On day 5,

TUNEL assay for apoptosis detection was performed using Click-iT Plus TUNEL Assay kit

(catalog#C10617, Invitrogen).

iPSC and NPC immunostaining

NPCs at passage 6 or iPSC clones were seeded on coverslips coated in PDL (1:1 in PBS) and

Geltrex (1:100 in DMEM/F12) in 6-well plates. Media was aspirated and cells were washed

using PBS three times. Cells were fixed in 4% paraformaldehyde (PFA) (catalog#158127,

Sigma-Aldrich) for 15 minutes, washed three times with PBS, then permeabilized in 0.2% Triton

X-100 (catalog#X100, Sigma-Aldrich) in PBS for 15 minutes. Blocking was done with a

solution of 2% BSA (catalog#A7906, Sigma-Aldrich), 0.2% Triton X-100, and 5% goat serum

(catalog# G9023, Sigma-Aldrich) in PBS for 1 hour at room temperature or overnight at 4 °C.

The coverslips were incubated with primary antibodies at room temperature for 2 hours or

overnight in the 4°C. Coverslips were washed with PBS three times for 5 minutes each, then

incubated with the secondary antibody for 2 hours at room temperature. Coverslips were again

washed in PBS three times and mounted using DAPI antifade mounting reagent. All antibodies

were diluted in blocking buffer. Antibodies: SOX2 (1:200, catalog#3579S Cell Signaling

Technology); NESTIN (1:800, catalog#33475S Cell Signaling Technology); NKX2.1 (1:200,

catalog#MAB5460, Millipore Sigma); PAX6 (1:800, catalog#60433S, Cell Signaling

Technology); TUBB3 (1:400, catalog#5568T, Cell Signaling Technology); FOXG1 (1:400,

calalog#29642S, Cell Signaling Technology); c-JUN (1:200, catalog#9165T, Cell Signaling

Technology); Ki-67 (1:200, catalog#9129T, Cell signaling Technology); SSEA4 (1:200,

catalog#4755T, Cell Signaling Technology); NANOG (1:500, catalog#4893T, Cell signaling

Technology); OCT4 (1:200, catalog#2750S, Cell Signaling Technology); Anti-mouse IgG (H+L),

F(ab')2 Fragment (1:1000,catalog #4408S, Cell Signaling Technology); Anti-rabbit IgG (H+L),

F(ab')2 Fragment (1:1000, catalog#8889S, Cell Signaling Technology).

Neuron immunostaining

Neurons were differentiated for 28 days then fixed with 20% PFA added directly to media to

reach a final concentration of 4% and incubated at room temperature for 15 minutes. PFA was

removed and cells were washed in PBS once for 5 minutes. 0.2% Triton X-100 in PBS was

added and incubated room temperature for 15 minutes to permeabilize. Triton X-100 was

removed, and cells were blocked at room temperature for 1 hour in 2% BSA, 0.2% Triton X-100,

and 5% goat serum in PBS. The coverslips were incubated with primary antibodies at room

temperature for 2 hours or overnight in the 4°C refrigerator. Coverslips were washed with PBS

two times for 5 minutes each, then incubated with the secondary antibody for 2 hours at room

temperature. Coverslips were again washed in PBS 2 times for 5 minutes each, then mounted

using DAPI antifade mounting reagent. All antibodies were diluted in blocking buffer.

Antibodies: MAP2 (1:500, catalog#4542S, Cell Signaling Technology); VGAT (1:250, Synaptic

Systems); VGLUT1 (1:500, Synaptic Systems). NeuN (1:400, catalog#94403S, Cell Signaling

Technology); Anti-mouse IgG (H+L), F(ab')2 Fragment (1:1000, catalog #4408S, Cell signaling

Technology); Anti-rabbit IgG (H+L), F(ab')2 Fragment (1:1000, catalog#8889S, Cell signaling

Technology).

Lentivirus packaging

HEK293T cells were grown in media containing DMEM (catalog#D6429, Sigma-Aldrich) and

10% FBS (catalog#F2442, Sigma-Aldrich), 1% Penicillin/Streptomycin. On day 0, cells were

seeded 18-24 hours prior to transfection to reach 80%-95% confluency on the day of

transfection. On day 1, fresh media was added 30 minutes prior to transfection. Transfection was

performed using TransIT-Lenti transfection Reagent (catalog#MIR6604, Mirus Bio), Opti-MEM

(catalog#31985070, Gibo), and LV-MAX Lentiviral Packaging Mix (catalog#A43237, Thermo

Fisher). On day 2, fresh media was added with ViralBoost Reagent (catalog#VB100, ALSTEM

CELL ADVANCEMENTS). On day 3, the supernatant was collected and centrifuged at room

temperature for 10 min at 300g to pellet debris and then the supernatant was passed through a

0.45um filter. Lentivirus Precipitation Solution (catalog#VC100, ALSTEM CELL

ADVANCEMENTS) was added to supernatant and a ratio of 1:4, mixed thoroughly, and

incubated overnight at 4°C, and then centrifuged for 30 min at 1500g at 4°C. The virus pellet

was diluted using mTESR1 medium and stored at -80°C.

RNA-seq sample processing and analysis

Each iPSC line was grown in three replicates, which were differentiated separately. RNA was

extracted from iPSCs, neural progenitor cells (NPCs; passage 5), and neurons differentiated from

NPCs at day 10 (iMNs) and day 28 (MNs). Only samples with RNA integrity number (RIN) ⩾

6.0, as measured by the Agilent TapeStation 4200 (Agilent Technologies), and purity (A260/280

ratio >1.8) were subjected to RNA sequencing. RNA sequencing libraries were prepared using

the NEBNext Ultra II RNA library Prep kit (#E7770S, NEB) for Illumina according to the

manufacturer's instructions. 150 base pair (bp) paired-end sequencing were performed using the

Illumina NovaSeq 6000 platform by Genewiz from Azenta Life Sciences (South Plainfield, NJ)

for 30 million reads. Trimmomatic v0.39[91] were used to trim adapters and to remove low-quality

reads (leading:3, trailing:3, slidingwindow:4:15, and minlen:36 parameters). Kallisto v.050.0[92]

with n=100 bootstrap samples was used to quantify the abundances of transcripts and hg38 cdna

was used to build the Kallisto index. Differential gene expression was analyzed using the

DEseq2 v1.44 package in R v.4.3.1[93]. Batch effects were corrected by Combat-seq using sva

v.3.35.2 package in R v.4.3.1[94].

Detection of alternative isoform usage

Alternative isoform usage was analyzed using the IsoformSwitchAnalyzeR v.2.4.0.[95] package in

R. Abundance files from Kallisto were input using the importIsoformExpression function. Genes

or isoforms under the cutoff were removed by the prefilter function at default settings. Isoform

switches were identified by isoformSwitchTestDEXseq function. To identify alternative isoform

usage events independent of overall gene expression changes, isoforms belonging to genes that

were also identified as DEGs were excluded.

Weighed gene co-expression network analysis (WGCNA)

WGCNA was performed using the WGCNA 1.72 package in R[96]. For WGCNA analysis using

the transcriptome data of NPC, iMN, and MN in Supplementary Figure 6A-B, first, raw counts

were normalized by variance stabilizing transformation (VST) from DEseq2 1.44 package in R.

The top 10,000 variable genes were extracted by median absolute deviation (MAD). The power

(β) was chosen by pickSoftThreshold function with an R.sq cutoff of 0.8. Signed hybrid co-

expression network (TOMType = "unsigned", minModuleSize = 100, mergeCutHeight =0.25)

was built by $a_{ij} = [cor(x_i, x_j)]^\beta$, for $cor(x_i, x_j) > 0$; $a_{ij} = 0$ for $cor(x_i, x_j) \leq 0$. Module eigengene was

calculated as the first principal component to represent the expression profiles in each model.

Pearson's correlation coefficient was used to assess correlations between modules and traits.

Whole genome sequencing (WGS) sample processing and analysis

DNA was isolated from blood samples from 22 participants and Illumina TruSeq DNA PCR-free

libraries (San Diego, CA, USA) were constructed for 150bp paired-end whole-genome

sequencing using Illumina HiSeq X by Macrogen Labs (Rockville, MD, USA). DNA from five

samples (HD_01, HD_02, CRISPR deletion, P2C_079, and FNC_079) were isolated from iPSC

cell lines using GenElute Mammalian Genomic DNA miniprep kits (#G1N79-1KT SIGMA). The

genomic DNA sample was broken into short fragments. These DNA fragments were then end-

polished, A-tailed, and ligated with full-length adapters for Illumina sequencing before further

size selection. PCR amplification was then conducted unless specified as PCR-free. Purification

was performed through the AMPure XP system. The resulting library was assessed on the

Agilent Fragment Analyzer System and quantified to 1.5nM through Qubit and qPCR. Whole

genome sequencing was conducted using Illumina Novaseq X by Novogene (Durham, NC,

USA). Samples were sequenced at an average 37.9X coverage, with an average of 810M reads

per sample and 98.0% of reads mapping to the human genome. We followed the GATK Best

Practices pipeline[97] to identify single nucleotide variants (SNVs) and small indels using GATK

v.4.5.0. GATK's MarkIlluminaAdapters was used to first mark adapter sequences and then align

the reads to the GRCh38 reference genome using BWA v.0.7.173[98]. Duplicate reads were

removed using the Picard implementation of MarkDuplicates and base quality score recalibration

was performed using the BaseRecalibrator and ApplyBQSR. HaplotypeCaller was used to call

variants for each sample, merge all variants into a single GVCF, and perform joint genotyping

using GenotypeGVCFs. We then used the Python API for Hail and Ensembl Variant Effect

Predictor (VEP) v.109[99] to annotate variants. After splitting multi-allelic sites, variants were

filtered for those with (i) ≥90% call rate, (ii) Hardy-Weinberg equilibrium p value ≥10-15, (iii)

read depth ≥8, and (iv) allele balance ≥0.2. Variants were further filtered for those with a

gnomAD v.2.17[100] frequency <0.1%. We annotated variant consequences based on transcript

consequences annotated by VEP and filtered for variants that were LOF ("transcript_ablation",

"stop_gained", "frameshift_variant", "stop_lost", "start_lost"), missense ("missense_variant"),

splice LOF ("splice_acceptor_variant", "splice_donor_variant"), splice

("splice_donor_5th_base_variant", "splice_region_variant", "splice_donor_region_variant",

"splice_polypyrimidine_tract_variant"), upstream ("upstream_gene_variant"), downstream

("downstream_gene_variant"), 5' UTR ("5_prime_UTR_variant"), 3' UTR

("3_prime_UTR_variant"), or intronic ("intron_variant"). We used dbNSFP8–10 v.4 annotations

to filter missense variants for those predicted to be deleterious by at least five of nine selected

tools (SIFT, LRT, FATHMM, PROVEAN, MetaSVM, MetaLR, PrimateAI, DEOGEN2, and

MutationAssessor). Variants were finally filtered for those private to related individuals to

account for any technical differences between our data and gnomAD. STRs were initially called

using GangSTR v2.5.0[101], followed by quality control and filtering with DumpSTR v6.0.1. STRs

with low-quality calls and those with read depths outside the range of 20 to 1000 were excluded

using the --gangstr-min-call-DP and --gangstr-max-call-DP parameters. Additional quality

control measures included filtering out all reads except spanning and bounding (--gangstr-filter-

spanbound-only) and filtering regions with poorly estimated confidence intervals (--gangstr-

filter-badCI). Individual VCF files were then merged into a multi-sample VCF using MergeSTR

v.6.0.1. To identify rare STRs, loci with an allele frequency of <0.1% in EnsembleTR

(https://github.com/gymrek-lab/EnsembleTR) were initially retained. Summary statistics were

calculated using StatSTR v.6.0.1[102]. For frequency >0.1%, only loci with repeat lengths

exceeding two standard deviations above the population mean were kept. Additionally, rare STRs

defined as those present in fewer than eight individuals in the iPSC cohort were selected for

downstream analysis. Final STR annotations were performed using ANNOVAR[103]. CNVs were

called using CNVpytor v.1.3.1[104] with bin size 500. Rare CNVs were defined as those with a

population frequency of <5% based on gnomAD v.4.1. CNV annotations were performed

manually, consistent with annotations generated by VEP and ANNOVAR, considering only

upstream, downstream, 3' UTR, 5' UTR, exonic, and intronic regions.

1024

Analysis of combined effects on gene expression

We assessed for combined effects by first extracting differentially expressed genes (padj<0.05)

by DESeq2 in individuals carrying both 16p12.1 deletion and the specific secondary variant

compared to all other individuals in the same family. Then, rare variants in those DEGs were

extracted and filtered by those which were inherited in the family. Next, two-way ANOVA (using

the statsmodels.formula.api and statsmodels.api modules in Python v.3.11.7) was performed

using TPM (Transcripts Per Million) of genes annotated from the filtered variants. Genes and

variants were kept only when the interaction p value (16p12.1 deletion: secondary hit",

"PR(>F)") was <0.05 using two-way ANOVA tests. The intersection of the variants with

Diffpeak regions was identified using Pybedtools[105]v.0.12.0.

1035

ATAC-seq sample processing and analysis

Live cell samples were collected and run through a 30 µm filter to obtain a single cell suspension

before cryopreservation. Thawed cells were washed and treated with DNAse I (Life Tech, Cat.

#EN0521) to remove genomic DNA contamination. Live cell samples were quantified and

assessed for viability using a Countess Automated Cell Counter (ThermoFisher Scientific,

Waltham, MA, USA). After cell lysis and cytosol removal, nuclei were treated with Tn5 enzyme

(Illumina, Cat. #20034197) for 30 minutes at 37°C and purified with Minelute PCR Purification

Kit (Qiagen, Cat. #28004) to produce tagmented DNA samples. Tagmented DNA was barcoded

with Nextera Index Kit v2 (Illumina, Cat. #FC-131-2001) and amplified via PCR prior to a SPRI

Bead cleanup to obtain purified DNA libraries. The sequencing libraries were multiplexed and

clustered onto a flow cell on the Illumina NovaSeq X and NovaSeq 6000 according to

manufacturer's instructions by Azenta Life Sciences (South Plainfield, NJ, USA). The samples

were sequenced using a 2x150bp Paired End (PE) configuration. Image analysis and base calling

were conducted by the NovaSeq Control Software (NCS). Raw sequence data (.bcl files)

generated from Illumina NovaSeq was converted into fastq files and de-multiplexed using

Illumina bcl2fastq 2.20 software. One mismatch was allowed for index sequence identification.

Quality control and processing of fastq sequencing files were performed using the ENCODE

ATAC-seq Data Standards and Processing Pipeline (https://github.com/ENCODE-DCC/atac-seq-

pipeline). DESeq2 was used to identify differential peaks. The cutoff for adjusted p value (padj)

was 0.01. Motif enrichment analysis was performed using the findMotifsGenome.pl from the

HOMER[106] on regions of Diffpeaks.

1057

ATAC-seq peak Annotation

We annotated ATAC-seq peaks using the union of three approaches: ChIPseeker[107] the Activity-

by-Contact (ABC) model[108], and nearest gene assignment. ChIPseeker analysis was performed

via Galaxy (version 1.28.3), using GENCODE Release 46 (GRCh38.p14) as the reference

genome annotation. The ABC model was applied using RNA-seq and ATAC-seq data from

HD_01 and HD_02 at the iPSC and NPC stages. Publicly available Hi-C and H3K27ac ChIP-seq

datasets were used as additional inputs for contact estimation and enhancer activity scoring[109,110].

Expressed genes were defined as those with expression >1 TPM and promoter activity

quantile >0.4. For each chromosome, enhancer–gene pairs within 5 Mb of a transcription start

site (TSS) were scored, and those with an ABC score above 0.022 (default threshold) were

retained as predicted regulatory interactions. Peak-to-gene associations were also established by

linking the nearest gene to peaks using the closest function from the Pybedtools.

1070

CRISPRa experiments

iPSCs derived from probands were first infected with lenti dCas9-VP64_Blast and lenti MS2-

P65-HSF1_Hygro. Lenti dCAS-VP64_Blast (Addgene plasmid # 61425;

http://n2t.net/addgene:61425; RRID: Addgene_61425) and lenti MS2-P65-HSF1_Hygro

(Addgene plasmid # 61426; http://n2t.net/addgene:61426; RRID: Addgene_61426)) were both

gifts from Feng Zhang. Then, cells were infected with lenti sgRNA (MS2) _Zeo. The EV line

was infected with only the backbone. To insert sgRNA, the backbone was digested with BsmBI-

v2 (NEB) and ligation was performed using quick ligase (NEB #M2200S) with phosphorylated

and annealed sgRNA. Lenti sgRNA (MS2) _Zeo backbone was a gift from Feng Zhang

(Addgene plasmid # 61427; http://n2t.net/addgene:61427; RRID: Addgene_61427). sgRNA

sequence: *POLR3E*: CACGGCCTGCATGAATGGCG; *MOSMO*:

GAGCCGGGAGGACGGAGCTG; *UQCRC2*: ATAAAGAGAGCAGTAGAGCG. All the

transductions were performed with 4µg/ml polybrene to improve efficiency. After 24hr

incubation, the medium was switched to fresh culture medium and incubated for another 48hr.

Selection was then performed at the iPSC stage using 10ng/ml Blasticidin, 250ng/ml

Hygromycin, 250ng/ml Zeocin until no further cell death was observed. Selection was repeated

using a half dose concentration from day 10 to day 12 of neural rosette formation during the

NPC differentiation protocol. Comparing CRISPRa lines to their corresponding EV controls

allowed us to identify DEGs resulting from the restoration of specific deletion genes in an

isogenic background. These DEGs were subsequently used in downstream functional analyses.

Additionally, we defined "reversed genes" as those DEGs from CRISPRa experiments that

exhibited changes in the opposite direction compared to DEGs identified in the proband line

compared to nondeletion sibling or healthy donor lines.

1094

PPI network analysis

Protein–protein interaction (PPI) network analysis was performed using the STRING database

with default settings (network type: full STRING network; required confidence score: ⩾0.400;

FDR stringency: medium, 5%). To create the density plot, the active interaction sources were text

mining, experiments, databases, co-expression, neighborhood, gene fusion, co-occurrence.

Anderson-Darling k-sample test was performed by ad.test function in kSamples v1.2-10 package

in R. To visualize the proteins involved in signal transduction based on Reactome data, active

interaction sources were experiments, databases and co-expression. Average node degree, PPI

enrichment p-value and functional enrichment were obtained from the STRING database.

1104

Enrichment analysis

We performed over-representation analysis (ORA) and gene set enrichment analysis (GSEA)

using clusterProfilter v.4.12.6 package in R, following the described guidelines[111]. For ORA, we

used enrichGO, entichKEGG, and enrichPathway functions. For GSEA, analysis was performed

against curated gene sets obtained using the msigdbr v.10.0.1 package in R. Pathway terms

belonging to Reactome, WP, and KEGG databases were extracted in an unbiased manner. For

generation of the waterfall plots in Figure 3G and Supplementary Figure 6D, the top 30 pathways

were unbiasedly selected from each database at the iPSC, NPC, iMN, and MN stages. These

pathways were then pooled, and the top 100 were selected based on q-value. If the number of

significantly enriched terms was fewer than 30 at each stage or fewer than 100 in total after

pooling, all enriched terms were included for generating waterfall plots. Enrichment analysis of

DEGs in published gene lists was performed using the GeneOverlap v.1.36.0[112] package in R.

Enrichment analysis of DEGs in DisGeNET was performed using enrichR v.3.4[113] package in R.

1118

Construction of TF regulatory networks for JUN and FOXG1

We used the ChEA3 (https://maayanlab.cloud/chea3/) web application to construct TF–TF co-

regulatory networks using the top 15 TFs whose binding motifs were significantly enriched in

Diffpeak regions from deletion lines versus HD lines comparisons at the NPC stage. In

comparisons where fewer than 15 motifs were enriched, only motifs with p-value less than 0.01

were included. FOXG1 and JUN ranked highest among the enriched transcription factors based

on the Integrated Scaled Rank. TF-TF co-regulatory networks were constructed by ChEA3 using

the top results, and edges between TFs defined by the evidence from libraries which supports the

interactions. To identify regulatory network genes for each TF, we input DEGs from each

comparison into ChEA3 and used the "Overlapping Genes" column. The top integrated rank

across ChEA3 libraries was used in our analysis.

1130

1131 **Imaging and quantification**

1132 Revolve (Discover Echo) was used to detect Click-iT signals. LSM 800 upright and LSM 800

1133 inverted (ZEISS) were used to detect fluorescence signals for immunofluorescence assays.

1134 Images were analyzed using Fiji (ImageJ).

1135

Statistics and reproducibility

Investigators were blinded to experimental condition when quantifying fluorescence intensity.

Comparisons between deletion carrier and noncarrier lines within the same family were used

when possible to control for the independent effects of shared secondary variants and to

specifically analyze the joint effects caused by both the 16p12.1 deletion and secondary variants.

Comparisons with healthy donor lines provided a consistent baseline across families and served

as appropriate controls for cellular assays and functional analysis, as many noncarrier lines also

exhibited clinical features due to the underlying genetic liability. The same bioinformatics

pipelines were applied across all conditions for each assay. Statistical analyses were conducted

using R v4.3.1 and Python v3.11.7. Details of the statistical tests and number of replicates are

provided in the corresponding figure legends and Supplementary Tables.

1147

Acknowledgments

The authors thank Dr. Yingwei Mao for valuable advice on iPSC culture and Dr. Melissa Rolls

for providing imaging resources. We are grateful to the National Institute of Neurological

Disorders and Stroke (NINDS) for supplying iPSC lines derived from healthy donors. The

authors thank Dr. Matthew Jensen, Dr. Francisca Canzar and Johnathan Ray for their assistance

and insights in data analysis. The following funding supported this study: NIH R01GM121907

and R21NS122398 (to S.G.)

1155

Author contributions

J.S. and S.G. conceived of and designed the study. S.G. supervised the experiments and analyses.

J.S., S.N. and M.D. maintained iPSC culture, performed the neural conversion and extracted

RNA. J.S., M.D. and A.P. generated the CRISPR-edited lines. J.S. and S.N. performed

immunostaining, imaging and image quantification. J.S., and V.H.B. performed assays on cell

proliferation and apoptosis. J.S. designed CRISPRa experiments and J.S., V.H.B. performed

CRISPRa experiments. J.S., D.B., C.S., and B.G. performed analyses on ATAC-seq, RNA-seq

and WGS. C.S. summarized the clinical phenotype information. D.A. and K.P. recruited 16p12.1

deletion families. P.L. reprogrammed iPSCs from PBMCs derived from recruited patients. J.S.,

S.N. and S.G. wrote the paper.

1166

Data and code availability

Whole genome sequencing, RNA-seq and ATAC-seq generated in this study are available at

NCBI dbGaP phs002403.v1.p1. All code generated for this project, including pipelines for

running bioinformatic software and custom analysis scripts, are available

at https://github.com/Jiawan1023/iPSC_integrated_framework. Detailed information of

statistical analyses is available in Supplementary Tables.

Supplementary Table 1:

Lists of DEGs and altered isoforms with secondary variants in the isogenic setting; Detailed
results of Fisher's exact tests in Figure 1C and volcano plots in Supplementary Figure 2A.

Supplementary Table 2:

Lists of Diffpeaks with secondary variants in the isogenic setting; Detailed results of Fisher's
exact tests in Figure 1D and volcano plots in Supplementary Figure 2B.

Supplementary Table 3:

Lists of TPM values of combined effects on gene expression across iPSC, NPC, iMN and MN
stages in the familial setting; Detailed results for Figure 1C.

Supplementary Table 4:

Lists of DEGs, reversed genes, GSEA results and ORA results in CRISPRa experiments.

Supplementary Table 5:

Lists of DEGs with secondary variants, and DEGs with secondary variants involved in signal
transductions for Figure 5.

Supplementary Table 6:

Lists of enriched motifs at the NPC stage, DEGs and Diffpeaks for Supplementary Figure 10B
and ChEA3 result.

Supplementary Table 7:

Lists of detailed results for WGCNA.

Supplementary Table 8:

Lists of DESeq2 results and GSEA results for each comparison, enrichment results using
published datasets and DisGeNET.

Supplementary Table 9:

Summary of all statistical tests.

1. Sun, J., Noss, S., Banerjee, D., Das, M. & Girirajan, S. Strategies for dissecting the
complexity of neurodevelopmental disorders. *Trends Genet* **40**, 187–202 (2024).

2. Kingdom, R., Beaumont, R. N., Wood, A. R., Weedon, M. N. & Wright, C. F. Genetic
modifiers of rare variants in monogenic developmental disorder loci. *Nat Genet* **56**, 861–868
(2024).

3. Girirajan, S. *et al.* Phenotypic heterogeneity of genomic disorders and rare copy-number
variants. *N Engl J Med* **367**, 1321–1331 (2012).

4. Bassett, A. S. & Chow, E. W. C. Schizophrenia and 22q11.2 deletion syndrome. *Curr
Psychiatry Rep* **10**, 148–157 (2008).

5. McDonald-McGinn, D. M. *et al.* 22q11.2 deletion syndrome. *Nat Rev Dis Primers* **1**, 15071
(2015).

6. Girirajan, S. *et al.* A recurrent 16p12.1 microdeletion supports a two-hit model for severe
developmental delay. *Nat Genet* **42**, 203–209 (2010).

7. Collins, R. L. *et al.* A cross-disorder dosage sensitivity map of the human genome. *Cell* **185**,
3041-3055.e25 (2022).

8. Rees, E. *et al.* Analysis of Intellectual Disability Copy Number Variants for Association With
Schizophrenia. *JAMA Psychiatry* **73**, 963–969 (2016).

9. Auwerx, C. *et al.* Rare copy-number variants as modulators of common disease susceptibility.
Genome Med **16**, 5 (2024).

10.   Stefansson, H. *et al.* CNVs conferring risk of autism or schizophrenia affect cognition in
controls. *Nature* **505**, 361–366 (2014).

11.   Montanucci, L. *et al.* Genome-wide identification and phenotypic characterization of
seizure-associated copy number variations in 741,075 individuals. *Nat Commun* **14**, 4392
(2023).

12.   Rees, E. *et al.* CNV analysis in a large schizophrenia sample implicates deletions at
16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. *Hum Mol Genet* **23**, 1669–
1676 (2014).

13.   Pizzo, L. *et al.* Rare variants in the genetic background modulate cognitive and
developmental phenotypes in individuals carrying disease-associated variants. *Genet Med* **21**,
816–825 (2019).

14.   Jensen, M. *et al.* Genetic modifiers and ascertainment drive variable expressivity of
complex disorders. 2024.08.27.24312158 Preprint at
https://doi.org/10.1101/2024.08.27.24312158 (2024).

15.   Qaiser, F. *et al.* Rare and low frequency genomic variants impacting neuronal functions
modify the Dup7q11.23 phenotype. *Orphanet J Rare Dis* **16**, 6 (2021).

16.   Taylor, C. M. *et al.* Phenotypic shift in copy number variants: Evidence in 16p11.2
duplication syndrome. *Genet Med* **25**, 151–154 (2023).

17.   Ardhanareeswaran, K., Mariani, J., Coppola, G., Abyzov, A. & Vaccarino, F. M. Human
induced pluripotent stem cells for modelling neurodevelopmental disorders. *Nat Rev Neurol*
13, 265–278 (2017).

18.   Deshpande, A. *et al.* Cellular Phenotypes in Human iPSC-Derived Neurons from a
Genetic Model of Autism Spectrum Disorder. *Cell Reports* **21**, 2678–2687 (2017).

19.   Wang, M. *et al.* Increased Neural Progenitor Proliferation in a hiPSC Model of Autism
Induces Replication Stress-Associated Genome Instability. *Cell Stem Cell* **26**, 221-233.e6
(2020).

20.   Nehme, R. *et al.* The 22q11.2 region regulates presynaptic gene-products linked to
schizophrenia. *Nat Commun* **13**, 3690 (2022).

21.   Habela, C. W., Song, H. & Ming, G.-L. Modeling synaptogenesis in schizophrenia and
autism using human iPSC derived neurons. *Mol Cell Neurosci* **73**, 52–62 (2016).

22.   Schafer, S. T. *et al.* Pathological priming causes developmental gene network
heterochronicity in autistic subject-derived neurons. *Nat Neurosci* **22**, 243–255 (2019).

23.   Hockemeyer, D. & Jaenisch, R. Induced Pluripotent Stem Cells Meet Genome Editing.
Cell Stem Cell **18**, 573–586 (2016).

24.   Peña, C. J. *et al.* Early life stress alters transcriptomic patterning across reward circuitry
in male and female mice. *Nat Commun* **10**, 5098 (2019).

25.   Krishnan, A. *et al.* Genome-wide prediction and functional characterization of the genetic
basis of autism spectrum disorder. *Nat Neurosci* **19**, 1454–1462 (2016).

26.   Parikshak, N. N. *et al.* Integrative functional genomic analyses implicate specific
molecular pathways and circuits in autism. *Cell* **155**, 1008–1021 (2013).

27.   Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
schizophrenia. *Nature* **604**, 502–508 (2022).

28.   Howard, D. M. *et al.* Genome-wide meta-analysis of depression identifies 102
independent variants and highlights the importance of the prefrontal brain regions. *Nat*
Neurosci **22**, 343–352 (2019).

29.   Pfisterer, U. *et al.* Identification of epilepsy-associated neuronal subtypes and gene
expression underlying epileptogenesis. *Nat Commun* **11**, 5038 (2020).

30.   Jensen, M. *et al.* Combinatorial patterns of gene expression changes contribute to variable expressivity of the developmental delay-associated 16p12.1 deletion. *Genome Med* **13**, 163 (2021).

31.   Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank participants. *Nature* **599**, 628–634 (2021).

32.   Campbell, R. F., McGrath, P. T. & Paaby, A. B. Analysis of Epistasis in Natural Traits Using Model Organisms. *Trends Genet* **34**, 883–898 (2018).

33.   Queitsch, C., Carlson, K. D. & Girirajan, S. Lessons from model organisms: phenotypic robustness and missing heritability in complex disease. *PLoS Genet* **8**, e1003041 (2012).

34.   Gibson, G. Decanalization and the origin of complex disease. *Nat Rev Genet* **10**, 134–140 (2009).

35.   Liu, Y. *et al.* Neuronal IFN-beta-induced PI3K/Akt-FoxA1 signalling is essential for generation of FoxA1+Treg cells. *Nat Commun* **8**, 14709 (2017).

36.   Bu, C. *et al.* c-Myb protects cochlear hair cells from cisplatin-induced damage via the PI3K/Akt signaling pathway. *Cell Death Discov* **8**, 78 (2022).

37.   Li, Y. *et al.* c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/β-Catenin/Axin2 Pathway. *Cancer Res* **76**, 3364–3375 (2016).

38.   Liu, C., Oikonomopoulos, A., Sayed, N. & Wu, J. C. Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond. *Development* **145**, dev156166 (2018).

39.   Zhang, S. *et al.* Multiple genes in a single GWAS risk locus synergistically mediate aberrant synaptic development and function in human neurons. *Cell Genom* **3**, 100399 (2023).

40.   Schrode, N. *et al.* Synergistic effects of common schizophrenia risk variants. *Nat Genet* **51**, 1475–1485 (2019).

41.   Mariani, J. *et al.* FOXG1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders. *Cell* **162**, 375–390 (2015).

42.   Ernst, C. Proliferation and Differentiation Deficits are a Major Convergence Point for Neurodevelopmental Disorders. *Trends Neurosci* **39**, 290–299 (2016).

43.   Schafer, S. T. *et al.* Pathological priming causes developmental gene network heterochronicity in autistic subject-derived neurons. *Nat Neurosci* **22**, 243–255 (2019).

44.   Jaaro-Peled, H. *et al.* Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. *Trends Neurosci* **32**, 485–495 (2009).

45.   Iyer, J. *et al.* Pervasive genetic interactions modulate neurodevelopmental defects of the
autism-associated 16p11.2 deletion in Drosophila melanogaster. *Nat Commun* **9**, 2548 (2018).

46.   Pizzo, L. *et al.* Functional assessment of the 'two-hit' model for neurodevelopmental
defects in Drosophila and X. laevis. *PLoS Genet* **17**, e1009112 (2021).

47.   Konermann, S. *et al.* Genome-scale transcriptional activation by an engineered CRISPR-
Cas9 complex. *Nature* **517**, 583–588 (2015).

48.   Ramanathan, A. *et al.* A mutation in POLR3E impairs antiviral immune response and
RNA polymerase III. *Proc Natl Acad Sci U S A* **117**, 22113–22121 (2020).

49.   Kong, J. H. *et al.* Gene-teratogen interactions influence the penetrance of birth defects by
altering Hedgehog signaling strength. *Development* **148**, dev199867 (2021).

50.   Gaignard, P. *et al.* UQCRC2 mutation in a patient with mitochondrial complex III
deficiency causing recurrent liver failure, lactic acidosis and hypoglycemia. *J Hum Genet* **62**,
729–731 (2017).

51.   Jing, J. *et al.* Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies.
Signal Transduct Target Ther **8**, 315 (2023).

52.   Pusapati, G. V. *et al.* CRISPR Screens Uncover Genes that Regulate Target Cell
Sensitivity to the Morphogen Sonic Hedgehog. *Dev Cell* **44**, 113-129.e8 (2018).

53.   Palma, V. *et al.* Sonic hedgehog controls stem cell behavior in the postnatal and adult
brain. *Development* **132**, 335–344 (2005).

54.   Sharma, J. *et al.* Neuronatin-mediated Aberrant Calcium Signaling and Endoplasmic
Reticulum Stress Underlie Neuropathology in Lafora Disease *. *Journal of Biological
Chemistry* **288**, 9482–9490 (2013).

55.   Furness, D. N. *et al.* Progressive hearing loss and gradual deterioration of sensory hair
bundles in the ears of mice lacking the actin-binding protein Eps8L2. *Proceedings of the
National Academy of Sciences* **110**, 13898–13903 (2013).

56.   Zhubi, A. *et al.* Increased binding of MeCP2 to the GAD1 and RELN promoters may be
mediated by an enrichment of 5-hmC in autism spectrum disorder (ASD) cerebellum. *Transl
Psychiatry* **4**, e349–e349 (2014).

57.   Jansen, L. A. *et al.* PI3K/AKT pathway mutations cause a spectrum of brain
malformations from megalencephaly to focal cortical dysplasia. *Brain* **138**, 1613–1628
(2015).

58.   Kwan, V., Unda, B. K. & Singh, K. K. Wnt signaling networks in autism spectrum
disorder and intellectual disability. *J Neurodev Disord* **8**, 45 (2016).

59.   Meyers, E. A. & Kessler, J. A. TGF-β Family Signaling in Neural and Neuronal
Differentiation, Development, and Function. *Cold Spring Harb Perspect Biol* **9**, a022244
(2017).

60.   Duronio, R. J. & Xiong, Y. Signaling pathways that control cell proliferation. *Cold Spring*
Harb Perspect Biol **5**, a008904 (2013).

61.   Szklarczyk, D. *et al.* The STRING database in 2023: protein-protein association networks
and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res*
51, D638–D646 (2023).

62.   Hollenbeck, P. J. Mitochondria and neurotransmission: evacuating the synapse. *Neuron*
47, 331–333 (2005).

63.   Zenisek, D. & Matthews, G. The role of mitochondria in presynaptic calcium handling at
a ribbon synapse. *Neuron* **25**, 229–237 (2000).

64.   Weidemüller, P., Kholmatov, M., Petsalaki, E. & Zaugg, J. B. Transcription factors:
Bridge between cell signaling and gene regulation. *Proteomics* **21**, e2000034 (2021).

65.   Perkins, K. K., Admon, A., Patel, N. & Tjian, R. The Drosophila Fos-related AP-1 protein
is a developmentally regulated transcription factor. *Genes Dev* **4**, 822–834 (1990).

66.   Freitas, R., Gómez-Marín, C., Wilson, J. M., Casares, F. & Gómez-Skarmeta, J. L.
Hoxd13 contribution to the evolution of vertebrate appendages. *Dev Cell* **23**, 1219–1229
(2012).

67.   Nowyhed, H. N. *et al.* The nuclear receptor nr4a1 controls CD8 T cell development
through transcriptional suppression of runx3. *Sci Rep* **5**, 9059 (2015).

68.   Rahman, M. S., Akhtar, N., Jamil, H. M., Banik, R. S. & Asaduzzaman, S. M. TGF-
β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone
formation. *Bone Res* **3**, 15005 (2015).

69.   Liao, G. *et al.* Jun NH2-terminal kinase (JNK) prevents nuclear beta-catenin
accumulation and regulates axis formation in Xenopus embryos. *Proc Natl Acad Sci U S A*
103, 16313–16318 (2006).

70.   Robertson, F. L. *et al.* Elevated FOXG1 in glioblastoma stem cells cooperates with
Wnt/β-catenin to induce exit from quiescence. *Cell Rep* **42**, 112561 (2023).

71.   Boyd, J. L. *et al.* Human-chimpanzee differences in a FZD8 enhancer alter cell-cycle
dynamics in the developing neocortex. *Curr Biol* **25**, 772–779 (2015).

72.   Maeda, Y., Isomura, A., Masaki, T. & Kageyama, R. Differential cell-cycle control by
oscillatory versus sustained Hes1 expression via p21. *Cell Rep* **42**, 112520 (2023).

73.   Narla, G. *et al.* KLF6, a candidate tumor suppressor gene mutated in prostate cancer.
1363   *Science* **294**, 2563–2566 (2001).

1364   74.   Yang, N. *et al.* Generation of pure GABAergic neurons by transcription factor
1365   programming. *Nat Methods* **14**, 621–628 (2017).

1366   75.   Zhang, X. *et al.* Local and global chromatin interactions are altered by large genomic
1367   deletions associated with human brain development. *Nat Commun* **9**, 5356 (2018).

1368   76.   Zhang, S. *et al.* Network Effects of the 15q13.3 Microdeletion on the Transcriptome and
1369   Epigenome in Human-Induced Neurons. *Biol Psychiatry* **89**, 497–509 (2021).

1370   77.   Wada, M. *et al.* Dopaminergic dysfunction and excitatory/inhibitory imbalance in
1371   treatment-resistant schizophrenia and novel neuromodulatory treatment. *Mol Psychiatry* **27**,
1372   2950–2967 (2022).

1373   78.   Kumar, S. *et al.* Impaired neurodevelopmental pathways in autism spectrum disorder: a
1374   review of signaling mechanisms and crosstalk. *J Neurodev Disord* **11**, 10 (2019).

1375   79.   Kalkman, H. O. A review of the evidence for the canonical Wnt pathway in autism
1376   spectrum disorders. *Mol Autism* **3**, 10 (2012).

1377   80.   Gao, R. & Penzes, P. Common mechanisms of excitatory and inhibitory imbalance in
1378   schizophrenia and autism spectrum disorders. *Curr Mol Med* **15**, 146–167 (2015).

1379   81.   Nussinov, R., Tsai, C.-J. & Jang, H. Neurodevelopmental disorders, immunity, and cancer
1380   are connected. *iScience* **25**, 104492 (2022).

1381   82.   Willsey, A. J. *et al.* Coexpression networks implicate human midfetal deep cortical
1382   projection neurons in the pathogenesis of autism. *Cell* **155**, 997–1007 (2013).

1383   83.   Naqvi, S. *et al.* Precise modulation of transcription factor levels identifies features
1384   underlying dosage sensitivity. *Nat Genet* **55**, 841–851 (2023).

1385   84.   Datlinger, P. *et al.* Pooled CRISPR screening with single-cell transcriptome readout. *Nat*
1386   *Methods* **14**, 297–301 (2017).

1387   85.   Replogle, J. M. *et al.* Combinatorial single-cell CRISPR screens by direct guide RNA
1388   capture and targeted sequencing. *Nat Biotechnol* **38**, 954–961 (2020).

1389   86.   Pașca, S. P. *et al.* A framework for neural organoids, assembloids and transplantation
1390   studies. *Nature* **639**, 315–320 (2025).

1391   87.   Hansen, J. A. Development and Psychometric Evaluation of the Hansen Research
1392   Services Matrix Adaptive Test: A Measure of Nonverbal IQ. *J Autism Dev Disord* **49**, 2721–
1393   2732 (2019).

88. Constantino, J. N. Social Responsiveness Scale. in *Encyclopedia of Autism Spectrum*
Disorders 2919–2929 (Springer, New York, NY, 2013). doi:10.1007/978-1-4419-1698-3_296.

89. Zubler, J. & Whitaker, T. CDC's Revised Developmental Milestone Checklists. *Am Fam*
Physician **106**, 370–371 (2022).

90. Bozaoglu, K. *et al.* Generation of seven iPSC lines from peripheral blood mononuclear
cells suitable to investigate Autism Spectrum Disorder. *Stem Cell Res* **39**, 101516 (2019).

91. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina
sequence data. *Bioinformatics* **30**, 2114–2120 (2014).

92. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq
quantification. *Nat Biotechnol* **34**, 525–527 (2016).

93. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).

94. Zhang, Y., Parmigiani, G. & Johnson, W. E. ComBat-seq: batch effect adjustment for
RNA-seq count data. *NAR Genom Bioinform* **2**, lqaa078 (2020).

95. Vitting-Seerup, K. & Sandelin, A. IsoformSwitchAnalyzeR: analysis of changes in
genome-wide patterns of alternative splicing and its functional consequences. *Bioinformatics*
35, 4469–4471 (2019).

96. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network
analysis. *BMC Bioinformatics* **9**, 559 (2008).

97. Van der Auwera, G. A. *et al.* From FastQ data to high confidence variant calls: the
Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics* **43**, 11.10.1-
11.10.33 (2013).

98. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler
transform. *Bioinformatics* **25**, 1754–1760 (2009).

99. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122 (2016).

100. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**,
285–291 (2016).

101. Mousavi, N., Shleizer-Burko, S., Yanicky, R. & Gymrek, M. Profiling the genome-wide
landscape of tandem repeat expansions. *Nucleic Acids Res* **47**, e90 (2019).

102. Mousavi, N. *et al.* TRTools: a toolkit for genome-wide analysis of tandem repeats.
Bioinformatics **37**, 731–733 (2021).

103. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic
variants from high-throughput sequencing data. *Nucleic Acids Res* **38**, e164 (2010).

104.   Suvakov, M., Panda, A., Diesh, C., Holmes, I. & Abyzov, A. CNVpytor: a tool for copy
1428   number variation detection and analysis from read depth and allele imbalance in whole-
1429   genome sequencing. *Gigascience* **10**, giab074 (2021).

1430   105.   Dale, R. K., Pedersen, B. S. & Quinlan, A. R. Pybedtools: a flexible Python library for
1431   manipulating genomic datasets and annotations. *Bioinformatics* **27**, 3423–3424 (2011).

1432   106.   Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime
1433   cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* **38**, 576–589
1434   (2010).

1435   107.   Yu, G., Wang, L.-G. & He, Q.-Y. ChIPseeker: an R/Bioconductor package for ChIP peak
1436   annotation, comparison and visualization. *Bioinformatics* **31**, 2382–2383 (2015).

1437   108.   Fulco, C. P. *et al.* Activity-by-contact model of enhancer-promoter regulation from
1438   thousands of CRISPR perturbations. *Nat Genet* **51**, 1664–1669 (2019).

1439   109.   Dixon, J. R. *et al.* Chromatin architecture reorganization during stem cell differentiation.
1440   *Nature* **518**, 331–336 (2015).

1441   110.   Xie, W. *et al.* Epigenomic analysis of multilineage differentiation of human embryonic
1442   stem cells. *Cell* **153**, 1134–1148 (2013).

1443   111.   Xu, S. *et al.* Using clusterProfiler to characterize multiomics data. *Nat Protoc* **19**, 3292–
1444   3320 (2024).

1445   112.   GeneOverlap. *Bioconductor* http://bioconductor.org/packages/GeneOverlap/.

1446   113.   Chen, E. Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment
1447   analysis tool. *BMC Bioinformatics* **14**, 128 (2013).

1448